US9096636B2
(en)
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
USRE44779E1
(en)
|
1997-03-07 |
2014-02-25 |
Santaris Pharma A/S |
Bicyclonucleoside and oligonucleotide analogues
|
JP3756313B2
(ja)
|
1997-03-07 |
2006-03-15 |
武 今西 |
新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
|
US6583168B1
(en)
|
1997-11-25 |
2003-06-24 |
Applera Corporation |
Sulfonated diarylrhodamine dyes
|
US6833361B2
(en)
|
1998-05-26 |
2004-12-21 |
Ribapharm, Inc. |
Nucleosides having bicyclic sugar moiety
|
EP1082012A4
(de)
|
1998-05-26 |
2002-01-16 |
Icn Pharmaceuticals |
Neue nukleoside mit bicyklischem zuckerteil
|
JP2003511466A
(ja)
*
|
1998-11-11 |
2003-03-25 |
パンセコ・アクティーゼルスカブ |
修飾pna分子
|
US6548651B1
(en)
|
1998-11-11 |
2003-04-15 |
Pantheco A/S |
Modified peptide nucleic acid (PNA) molecules
|
CZ296576B6
(cs)
|
1999-02-12 |
2006-04-12 |
Sankyo Company Limited |
Nukleosidový analog a oligonukleotidový analog a farmaceutický prostredek, sonda a primer s jeho obsahem
|
JP4148662B2
(ja)
*
|
2000-08-10 |
2008-09-10 |
第一三共株式会社 |
ヌクレオシド及びオリゴヌクレオチド類縁体を含有する核酸試薬及び医薬
|
US7084125B2
(en)
|
1999-03-18 |
2006-08-01 |
Exiqon A/S |
Xylo-LNA analogues
|
CA2366231C
(en)
|
1999-03-18 |
2010-05-11 |
Exiqon A/S |
One step sample preparation and detection of nucleic acids in complex biological samples
|
ATE501269T1
(de)
|
1999-03-18 |
2011-03-15 |
Exiqon As |
Detektion von genmutationen mittels lna primer
|
DE60044241D1
(de)
*
|
1999-03-18 |
2010-06-02 |
Exiqon As |
Xylo-lna analoge
|
US6734291B2
(en)
|
1999-03-24 |
2004-05-11 |
Exiqon A/S |
Synthesis of [2.2.1]bicyclo nucleosides
|
DK1163250T3
(da)
|
1999-03-24 |
2006-11-13 |
Exiqon As |
Forbedret syntese af [2.2.1]bicyclonukleosider
|
US7098192B2
(en)
|
1999-04-08 |
2006-08-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of STAT3 expression
|
ATE356824T1
(de)
*
|
1999-05-04 |
2007-04-15 |
Santaris Pharma As |
L-ribo-lna analoge
|
US6525191B1
(en)
|
1999-05-11 |
2003-02-25 |
Kanda S. Ramasamy |
Conformationally constrained L-nucleosides
|
DE19926154A1
(de)
|
1999-06-09 |
2000-12-14 |
Ktb Tumorforschungs Gmbh |
Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
|
US6593466B1
(en)
|
1999-07-07 |
2003-07-15 |
Isis Pharmaceuticals, Inc. |
Guanidinium functionalized nucleotides and precursors thereof
|
JP4151751B2
(ja)
|
1999-07-22 |
2008-09-17 |
第一三共株式会社 |
新規ビシクロヌクレオシド類縁体
|
WO2001025478A1
(en)
*
|
1999-10-04 |
2001-04-12 |
Exiqon A/S |
A method of increasing the specificity of oxy-lna oligonucleotides
|
JP2003511016A
(ja)
*
|
1999-10-04 |
2003-03-25 |
エクシコン エ/エス |
オリゴヌクレオチドを補充する高親和性rnアーゼhの設計
|
EP1240322A2
(de)
*
|
1999-12-23 |
2002-09-18 |
Exiqon A/S |
Therapeutische anwendungen von lna-modifizierten oligonukleotiden
|
US8273866B2
(en)
|
2002-02-20 |
2012-09-25 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
|
US8202979B2
(en)
|
2002-02-20 |
2012-06-19 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
|
EP1268768A2
(de)
*
|
2000-03-27 |
2003-01-02 |
University Of Delaware |
Gezielte chromosomale genom-änderungen mit modifizierten einzelsträngigen oligonukleotiden
|
US6936467B2
(en)
|
2000-03-27 |
2005-08-30 |
University Of Delaware |
Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
|
DK1309726T4
(en)
|
2000-03-30 |
2019-01-28 |
Whitehead Inst Biomedical Res |
RNA Sequence-Specific Mediators of RNA Interference
|
US6887664B2
(en)
|
2000-06-06 |
2005-05-03 |
Applera Corporation |
Asynchronous primed PCR
|
JP2002322192A
(ja)
*
|
2000-08-10 |
2002-11-08 |
Sankyo Co Ltd |
2’−o,4’−c−架橋ヌクレオシドトリリン酸体
|
US6998484B2
(en)
|
2000-10-04 |
2006-02-14 |
Santaris Pharma A/S |
Synthesis of purine locked nucleic acid analogues
|
ATE431355T1
(de)
|
2000-10-11 |
2009-05-15 |
Applera Corp |
Fluoreszierende nukleobasekonjugate mit anionische linker
|
CZ308053B6
(cs)
|
2000-12-01 |
2019-11-27 |
Max Planck Gesellschaft |
Izolovaná molekula dvouřetězcové RNA, způsob její výroby a její použití
|
US6720148B1
(en)
|
2001-02-22 |
2004-04-13 |
Caliper Life Sciences, Inc. |
Methods and systems for identifying nucleotides by primer extension
|
EP1247815A3
(de)
*
|
2001-03-25 |
2003-01-29 |
Exiqon A/S |
Modifizierte Oligonukleotide sowie deren Verwendung
|
AU2002303176A1
(en)
|
2001-03-27 |
2002-10-15 |
University Of Delaware |
Genomics applications for modified oligonucleotides
|
WO2002079467A2
(en)
*
|
2001-03-29 |
2002-10-10 |
Københavns Universitet |
Antibiotic-free bacterial strain selection with antisense molecules
|
EP1251183A3
(de)
*
|
2001-04-18 |
2003-12-10 |
Exiqon A/S |
Verbesserte Helfersonden zur Detektion einer Zielsequenz mittels Fangoligonukleotid
|
US7109165B2
(en)
|
2001-05-18 |
2006-09-19 |
Sirna Therapeutics, Inc. |
Conjugates and compositions for cellular delivery
|
US20050148530A1
(en)
|
2002-02-20 |
2005-07-07 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
AU2002317437A1
(en)
*
|
2001-05-18 |
2002-12-03 |
Cureon A/S |
Therapeutic uses of lna-modified oligonucleotides in infectious diseases
|
US9994853B2
(en)
|
2001-05-18 |
2018-06-12 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
US20030032028A1
(en)
*
|
2001-06-12 |
2003-02-13 |
Gayle Dace |
In vitro capture of nucleic acids via modified oligonucleotides and magnetic beads
|
US7053195B1
(en)
|
2001-06-12 |
2006-05-30 |
Syngenta Participatious Ag |
Locked nucleic acid containing heteropolymers and related methods
|
WO2002101041A1
(fr)
*
|
2001-06-12 |
2002-12-19 |
Takara Bio Inc. |
Procede d'amplification de l'acide nucleique et procede de detection du polymorphisme des nucleotides a l'aide d'un analogue de nucleotide
|
GB0114719D0
(en)
*
|
2001-06-15 |
2001-08-08 |
Glaxo Group Ltd |
Compound
|
EP2000482A1
(de)
|
2001-06-20 |
2008-12-10 |
Genentech, Inc. |
Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
|
EP1404698A4
(de)
|
2001-06-21 |
2004-12-22 |
Isis Pharmaceuticals Inc |
Antisense-modulation von superoxiddismutase 1, expression in lösung
|
US7153954B2
(en)
|
2001-07-12 |
2006-12-26 |
Santaris Pharma A/S |
Method for preparation of LNA phosphoramidites
|
CA2921821A1
(en)
|
2001-07-12 |
2003-01-23 |
University Of Massachusetts |
In vivo production of small interfering rnas that mediate gene silencing
|
US6822088B2
(en)
|
2001-07-17 |
2004-11-23 |
Isis Pharmaceuticals, Inc. |
Synthesis of oligonucleotides on solid support
|
US6964950B2
(en)
|
2001-07-25 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of C-reactive protein expression
|
US7425545B2
(en)
|
2001-07-25 |
2008-09-16 |
Isis Pharmaceuticals, Inc. |
Modulation of C-reactive protein expression
|
US20030096772A1
(en)
|
2001-07-30 |
2003-05-22 |
Crooke Rosanne M. |
Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
|
US7407943B2
(en)
|
2001-08-01 |
2008-08-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein B expression
|
US7227014B2
(en)
|
2001-08-07 |
2007-06-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein (a) expression
|
CA2459347C
(en)
|
2001-09-04 |
2012-10-09 |
Exiqon A/S |
Locked nucleic acid (lna) compositions and uses thereof
|
NZ531674A
(en)
|
2001-09-18 |
2009-03-31 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of tumor
|
US7414111B2
(en)
|
2001-09-19 |
2008-08-19 |
Alexion Pharmaceuticals, Inc. |
Engineered templates and their use in single primer amplification
|
DK1436404T3
(da)
|
2001-09-19 |
2010-03-08 |
Alexion Pharma Inc |
Manipulerede templates og deres anvendelse i single-primer amplifikation
|
US7468244B2
(en)
|
2001-09-27 |
2008-12-23 |
University Of Delaware |
Polymorphism detection and separation
|
US7112405B2
(en)
|
2001-09-27 |
2006-09-26 |
University Of Delaware |
Compositions and methods for enhancing oligonucleotide-mediated gene alteration
|
US6750019B2
(en)
|
2001-10-09 |
2004-06-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of insulin-like growth factor binding protein 5 expression
|
AU2002334895B2
(en)
|
2001-10-09 |
2006-10-19 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of insulin-like growth factor binding protein 5 expression
|
WO2003033696A1
(fr)
*
|
2001-10-18 |
2003-04-24 |
Sankyo Company, Limited |
Compose antisens vegf
|
AU2002351077A1
(en)
*
|
2001-11-05 |
2003-05-19 |
Exiqon A/S |
Oligonucleotides modified with novel alpha-l-rna analogues
|
WO2003040395A2
(en)
|
2001-11-07 |
2003-05-15 |
Applera Corporation |
Universal nucleotides for nucleic acid analysis
|
EP1448800A4
(de)
|
2001-11-21 |
2007-05-16 |
Applera Corp |
Digitaler assay
|
US6965025B2
(en)
|
2001-12-10 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of connective tissue growth factor expression
|
EP1463829A1
(de)
*
|
2001-12-19 |
2004-10-06 |
Quantibact A/S |
Verfahren und kit zur bestimmung einer mikrobenzahl
|
KR100623128B1
(ko)
|
2002-01-02 |
2006-09-14 |
제넨테크, 인크. |
종양의 진단 및 치료 방법 및 이를 위한 조성물
|
US9181551B2
(en)
|
2002-02-20 |
2015-11-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
AU2003207708A1
(en)
|
2002-02-20 |
2003-09-09 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of map kinase genes
|
US9657294B2
(en)
|
2002-02-20 |
2017-05-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
WO2003075856A2
(en)
|
2002-03-07 |
2003-09-18 |
University Of Delaware |
Methods, compositions, and kits for enhancing oligonucleotide-mediated nucleic acid sequence alteration using compositions comprising a histone deacetylase inhibitor, lambda phage beta protein, or hydroxyurea
|
EP2264172B1
(de)
|
2002-04-05 |
2017-09-27 |
Roche Innovation Center Copenhagen A/S |
Oligomere zur modulation von hif-1 alpha expression
|
AU2003230874A1
(en)
|
2002-04-16 |
2003-11-03 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US7569575B2
(en)
|
2002-05-08 |
2009-08-04 |
Santaris Pharma A/S |
Synthesis of locked nucleic acid derivatives
|
US7199107B2
(en)
|
2002-05-23 |
2007-04-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of kinesin-like 1 expression
|
US20040014108A1
(en)
*
|
2002-05-24 |
2004-01-22 |
Eldrup Anne B. |
Oligonucleotides having modified nucleoside units
|
AU2003237249A1
(en)
*
|
2002-05-24 |
2003-12-12 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having modified nucleoside units
|
WO2003106477A1
(en)
*
|
2002-06-01 |
2003-12-24 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation
|
US7005265B1
(en)
|
2002-06-20 |
2006-02-28 |
Wenhong Fan |
Nonenzymatic catalytic signal amplification for nucleic acid hybridization assays
|
AU2003288474A1
(en)
*
|
2002-06-24 |
2004-03-19 |
Exiqon A/S |
Methods and systems for detection and isolation of a nucleotide sequence
|
FI20021325A0
(fi)
|
2002-07-05 |
2002-07-05 |
Valtion Teknillinen |
Menetelmä ja reagenssipakkaus yksittäisten polynukleotidien määrän määrittämiseksi
|
US7956176B2
(en)
|
2002-09-05 |
2011-06-07 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
EA008940B1
(ru)
|
2002-09-13 |
2007-10-26 |
Репликор, Инк. |
Антивирусные олигонуклеотиды, не связанные с комплементарностью последовательностей
|
WO2004031350A2
(en)
|
2002-09-26 |
2004-04-15 |
Amgen, Inc. |
Modulation of forkhead box o1a expression
|
WO2004035819A2
(en)
*
|
2002-10-21 |
2004-04-29 |
Exiqon A/S |
Oligonucleotide analogues for detecting and analyzing nucleic acids
|
US20040219565A1
(en)
|
2002-10-21 |
2004-11-04 |
Sakari Kauppinen |
Oligonucleotides useful for detecting and analyzing nucleic acids of interest
|
US9150606B2
(en)
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
|
CA2504694C
(en)
|
2002-11-05 |
2013-10-01 |
Isis Pharmaceuticals, Inc. |
Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
US9150605B2
(en)
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
|
WO2004044132A2
(en)
|
2002-11-05 |
2004-05-27 |
Isis Pharmaceuticals, Inc. |
Modified oligonucleotides for use in rna interference
|
ES2420914T3
(es)
|
2002-11-13 |
2013-08-27 |
Genzyme Corporation |
Modulación antisentido de la expresión de la apolipoproteína B
|
AU2003294281B2
(en)
|
2002-11-13 |
2010-05-20 |
Kastle Therapeutics, Llc |
Antisense modulation of apolipoprotein B expression
|
US7511131B2
(en)
|
2002-11-13 |
2009-03-31 |
Genzyme Corporation |
Antisense modulation of apolipoprotein B expression
|
ES2607471T3
(es)
|
2002-11-18 |
2017-03-31 |
Roche Innovation Center Copenhagen A/S |
Diseño antisentido
|
US7144999B2
(en)
|
2002-11-23 |
2006-12-05 |
Isis Pharmaceuticals, Inc. |
Modulation of hypoxia-inducible factor 1 alpha expression
|
ES2566632T3
(es)
|
2002-11-25 |
2016-04-14 |
Masafumi Matsuo |
Fármacos de ácido nucleico ENA que modifican el corte y empalme en precursores de ARNm
|
US20040115634A1
(en)
|
2002-12-11 |
2004-06-17 |
Isis Pharmaceuticals, Inc. |
Modulation of stat 6 expression
|
PT1592793E
(pt)
|
2003-02-10 |
2009-09-30 |
Santaris Pharma As |
Compostos oligoméricos para a modulação da expressão de survivina
|
US7713738B2
(en)
|
2003-02-10 |
2010-05-11 |
Enzon Pharmaceuticals, Inc. |
Oligomeric compounds for the modulation of survivin expression
|
WO2004072284A1
(en)
|
2003-02-11 |
2004-08-26 |
Antisense Therapeutics Ltd |
Modulation of insulin like growth factor i receptor expression
|
WO2004074503A2
(en)
*
|
2003-02-21 |
2004-09-02 |
Hoser Mark J |
Nucleic acid sequencing methods, kits and reagents
|
US7803781B2
(en)
|
2003-02-28 |
2010-09-28 |
Isis Pharmaceuticals, Inc. |
Modulation of growth hormone receptor expression and insulin-like growth factor expression
|
CA2519860C
(en)
|
2003-03-21 |
2018-01-16 |
Santaris Pharma A/S |
Short interfering rna (sirna) analogues
|
US20040185559A1
(en)
|
2003-03-21 |
2004-09-23 |
Isis Pharmaceuticals Inc. |
Modulation of diacylglycerol acyltransferase 1 expression
|
WO2004096124A2
(en)
|
2003-04-01 |
2004-11-11 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
US7399853B2
(en)
|
2003-04-28 |
2008-07-15 |
Isis Pharmaceuticals |
Modulation of glucagon receptor expression
|
CA2524495A1
(en)
|
2003-06-03 |
2005-01-13 |
Eli Lilly And Company |
Modulation of survivin expression
|
US7799525B2
(en)
|
2003-06-17 |
2010-09-21 |
Human Genetic Signatures Pty Ltd. |
Methods for genome amplification
|
ES2385828T3
(es)
|
2003-06-20 |
2012-08-01 |
Exiqon A/S |
Sondas, bibliotecas y kits para análisis de mezclas de ácidos nucleicos y procedimientos para construirlos
|
WO2005013901A2
(en)
|
2003-07-31 |
2005-02-17 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and compositions for use in modulation of small non-coding rnas
|
US7825235B2
(en)
|
2003-08-18 |
2010-11-02 |
Isis Pharmaceuticals, Inc. |
Modulation of diacylglycerol acyltransferase 2 expression
|
JP4731324B2
(ja)
|
2003-08-28 |
2011-07-20 |
武 今西 |
N−o結合性架橋構造型新規人工核酸
|
DE602004018801D1
(de)
|
2003-09-04 |
2009-02-12 |
Human Genetic Signatures Pty |
Nukleinsäurenachweistest
|
US20050053981A1
(en)
*
|
2003-09-09 |
2005-03-10 |
Swayze Eric E. |
Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
|
NZ576775A
(en)
|
2003-09-18 |
2010-12-24 |
Isis Pharmaceuticals Inc |
Modulation of eIF4E expression
|
US20050191653A1
(en)
|
2003-11-03 |
2005-09-01 |
Freier Susan M. |
Modulation of SGLT2 expression
|
EP1688493B1
(de)
|
2003-11-07 |
2008-08-13 |
Daiichi Sankyo Company, Limited |
Verfahren zum nachweis von genetischem polymorphismus
|
US7439341B2
(en)
|
2003-11-14 |
2008-10-21 |
Integrated Dna Technologies, Inc. |
Fluorescence quenching azo dyes, their methods of preparation and use
|
EP1689432B1
(de)
|
2003-11-17 |
2009-12-30 |
Genentech, Inc. |
Zusammensetzungen und verfahren zur behandlung von tumoren hämatopoetischen ursprungs
|
US7504495B2
(en)
|
2003-11-20 |
2009-03-17 |
Exiqon A/S |
Quencher compositions comprising anthraquinone moieties
|
AU2004303464B2
(en)
|
2003-12-23 |
2009-10-01 |
Santaris Pharma A/S |
Oligomeric compounds for the modulation of BCL-2
|
EP2363480A3
(de)
|
2004-01-20 |
2015-10-07 |
Isis Pharmaceuticals, Inc. |
Modulierung der Glukokortikoid-Rezeptor-Expression
|
CA2554212A1
(en)
|
2004-02-10 |
2005-08-25 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using multifunctional short interfering nucleic acid (multifunctional sina)
|
US20070265220A1
(en)
*
|
2004-03-15 |
2007-11-15 |
City Of Hope |
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
|
EP1730309B1
(de)
|
2004-03-15 |
2016-05-04 |
Ionis Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur optimierung der spaltung von rna durch rnase h
|
US8192937B2
(en)
|
2004-04-07 |
2012-06-05 |
Exiqon A/S |
Methods for quantification of microRNAs and small interfering RNAs
|
CA2557532A1
(en)
|
2004-04-23 |
2005-11-10 |
Angela M. Christiano |
Inhibition of hairless protein mrna
|
US8168777B2
(en)
|
2004-04-29 |
2012-05-01 |
Human Genetic Signatures Pty. Ltd. |
Bisulphite reagent treatment of nucleic acid
|
US20050287558A1
(en)
|
2004-05-05 |
2005-12-29 |
Crooke Rosanne M |
SNPs of apolipoprotein B and modulation of their expression
|
US10508277B2
(en)
|
2004-05-24 |
2019-12-17 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
US8394947B2
(en)
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
US7884086B2
(en)
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
DE602005022740D1
(de)
|
2004-09-10 |
2010-09-16 |
Human Genetic Signatures Pty |
Amplifikationsblocker umfassend interkalierende nukleinsäuren (ina) enthaltend interkalierende pseudonukleotide (ipn)
|
CA2581174A1
(en)
|
2004-09-16 |
2006-03-30 |
Applera Corporation |
Fluorescent dye compounds, conjugates and uses thereof
|
US9447138B2
(en)
|
2004-11-09 |
2016-09-20 |
Roche Innovation Center Copenhagen A/S |
Potent LNA oligonucleotides for the inhibition of HIF-1a expression
|
KR20070095882A
(ko)
|
2004-11-09 |
2007-10-01 |
산타리스 팔마 에이/에스 |
Lna 올리고뉴클레오티드 및 암의 치료
|
EP1833840B9
(de)
|
2004-11-09 |
2010-11-10 |
Santaris Pharma A/S |
Wirksame lna-oligonukleotide zur inhibierung von hif-1a
|
JP5116481B2
(ja)
|
2004-12-03 |
2013-01-09 |
ヒューマン ジェネティック シグネチャーズ ピーティーワイ リミテッド |
シトシンの化学修飾により微生物核酸を簡素化するための方法
|
EP1838870A2
(de)
|
2004-12-29 |
2007-10-03 |
Exiqon A/S |
Neue oligonukleotidzusammensetzungen und sondensequenzen mit eignung zum nachweis und zur analyse von micrornas und ihren ziel-mrnas
|
EP2813581B1
(de)
|
2005-01-06 |
2018-06-27 |
Applied Biosystems, LLC |
Verwendung von Polypeptiden mit Nukleinsäurebindungsaktivität in Verfahren schneller Nukleinsäurenamplifikation
|
CA2597325A1
(en)
|
2005-03-10 |
2006-09-21 |
Genentech, Inc. |
Methods and compositions for modulating vascular integrity
|
US20090264635A1
(en)
|
2005-03-25 |
2009-10-22 |
Applera Corporation |
Methods and compositions for depleting abundant rna transcripts
|
TWI335352B
(en)
|
2005-03-31 |
2011-01-01 |
Calando Pharmaceuticals Inc |
Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
|
EP1902142B1
(de)
|
2005-04-14 |
2010-01-06 |
Applied Biosystems, LLC |
3'-modifizierte oligonukleotide mit pseudoisocytosin-nukleobasenderivaten sowie deren anwendungen als primer oder sonden
|
US7838502B2
(en)
|
2005-05-06 |
2010-11-23 |
University Of Massachusetts Medical School |
Compositions and methods to modulate H. influenzae pathogenesis
|
AU2006247739A1
(en)
|
2005-05-11 |
2006-11-23 |
Vector Tobacco Inc. |
Reduced risk tobacco products and methods of making same
|
EP1888773A2
(de)
|
2005-05-11 |
2008-02-20 |
Arhus Universitet |
Verfahren zur diagnose und behandlung einer geisteskrankheit
|
CA2601554A1
(en)
|
2005-05-20 |
2006-11-30 |
Integrated Dna Technologies, Inc. |
Compounds and methods for labeling oligonucleotides
|
JP5284084B2
(ja)
*
|
2005-05-25 |
2013-09-11 |
ティナ・ホールディング・アーペーエス |
ねじれたインターカレーティング核酸(tina)を用いた、フーグスティーン型の三重鎖および二重鎖の安定でそして選択的な形成、ならびにtinaの調製法
|
AU2006251866B2
(en)
|
2005-05-26 |
2007-11-29 |
Human Genetic Signatures Pty Ltd |
Isothermal strand displacement amplification using primers containing a non-regular base
|
JP5329949B2
(ja)
|
2005-05-31 |
2013-10-30 |
エコーレ ポリテクニーク フェデラーレ デ ローザンヌ |
遺伝子に基づいた薬物の細胞質送達のためのトリブロックコポリマー
|
US8252756B2
(en)
|
2005-06-14 |
2012-08-28 |
Northwestern University |
Nucleic acid functionalized nanoparticles for therapeutic applications
|
WO2007011901A2
(en)
|
2005-07-15 |
2007-01-25 |
Applera Corporation |
Hot start reverse transcription by primer design
|
US7745122B2
(en)
|
2005-07-15 |
2010-06-29 |
Applied Biosystems, Llc |
Analyzing messenger RNA and micro RNA in the same reaction mixture
|
KR20080036646A
(ko)
|
2005-08-17 |
2008-04-28 |
메덱시스 에스.에이. |
Ck19 발현 측정을 위한 조성물 및 방법
|
DE602006019455D1
(de)
|
2005-08-29 |
2011-02-17 |
Regulus Therapeutics Inc |
Verfahren für mir-122a-modulation
|
EP1931780B1
(de)
|
2005-08-29 |
2016-01-06 |
Regulus Therapeutics Inc. |
Antisense-verbindungen mit verbesserter anti-mikrorna-aktivität
|
WO2007026823A1
(ja)
*
|
2005-08-31 |
2007-03-08 |
Osaka University |
人工核酸プローブを用いた三重鎖核酸形成を基盤とした標的核酸の検出
|
US20070059713A1
(en)
|
2005-09-09 |
2007-03-15 |
Lee Jun E |
SSB-DNA polymerase fusion proteins
|
WO2007030882A1
(en)
|
2005-09-14 |
2007-03-22 |
Human Genetic Signatures Pty Ltd |
Assay for a health state
|
JP5438320B2
(ja)
|
2005-10-03 |
2014-03-12 |
アプライド バイオシステムズ リミテッド ライアビリティー カンパニー |
核酸を増幅するための組成物、方法およびキット
|
JP5623016B2
(ja)
|
2005-12-01 |
2014-11-12 |
プロネイ・セラピューティクス・インコーポレイテッドPronaitherapeutics, Inc. |
癌治療法およびそれに用いる医薬組成物
|
EP2206779B1
(de)
|
2005-12-06 |
2013-02-13 |
Life Technologies Corporation |
Rückübertragungs-Primer und Verfahren zu deren Entwurf
|
WO2007073149A1
(en)
|
2005-12-22 |
2007-06-28 |
Keygene N.V. |
Alternative nucleotides for improved targeted nucleotide exchange
|
WO2007087113A2
(en)
|
2005-12-28 |
2007-08-02 |
The Scripps Research Institute |
Natural antisense and non-coding rna transcripts as drug targets
|
PL2314594T3
(pl)
*
|
2006-01-27 |
2014-12-31 |
Isis Pharmaceuticals Inc |
Zmodyfikowane w pozycji 6 analogi bicykliczne kwasów nukleinowych
|
EP1984499B1
(de)
|
2006-01-27 |
2015-05-27 |
Isis Pharmaceuticals, Inc. |
Oligomere verbindungen und zusammensetzungen zur verwendung bei der modulation von mikro-rnas
|
US8669345B2
(en)
|
2006-01-27 |
2014-03-11 |
Biogen Idec Ma Inc. |
Nogo receptor antagonists
|
EP1994182B1
(de)
|
2006-03-15 |
2019-05-29 |
Siemens Healthcare Diagnostics Inc. |
Abgleit-nucleobase-analoga
|
CA2645136C
(en)
|
2006-03-16 |
2017-09-19 |
Pentabase Aps |
Oligonucleotides comprising signalling pairs and hydrophobic nucleotides, stemless beacons, for detection of nucleic acids, methylation status and mutants of nucleic acids
|
US8329888B2
(en)
|
2006-03-23 |
2012-12-11 |
Santaris Pharma A/S |
Small internally segmented interfering RNA
|
MY162210A
(en)
|
2006-04-03 |
2017-05-31 |
Roche Innovation Ct Copenhagen As |
Pharmaceutical composition
|
MX2008012219A
(es)
|
2006-04-03 |
2008-10-02 |
Santaris Pharma As |
Composicion farmaceutica que comprende oligonucleotidos antisentido anti-miarn.
|
EP2360277A1
(de)
|
2006-05-03 |
2011-08-24 |
Geisinger Clinic |
Diagnose- und Prognoseverfahren für nichtalkoholische Steatohepatitis (NASH)
|
EP2505649A1
(de)
|
2006-05-05 |
2012-10-03 |
Isis Pharmaceuticals, Inc. |
Verbindungen und Verfahren zur Modulation der Expression von GCGR
|
JP2009536222A
(ja)
|
2006-05-05 |
2009-10-08 |
アイシス ファーマシューティカルズ, インコーポレーテッド |
Pcsk9の発現を調節するための化合物および方法
|
CA2651453C
(en)
|
2006-05-11 |
2014-10-14 |
Isis Pharmaceuticals, Inc. |
5'-modified bicyclic nucleic acid analogs
|
CA2659301A1
(en)
|
2006-07-28 |
2008-02-07 |
Applera Corporation |
Dinucleotide mrna cap analogs
|
EP2484781B1
(de)
|
2006-08-01 |
2017-08-23 |
Applied Biosystems, LLC |
Nachweis von Analyten und Nukleinsäuren
|
US7947487B2
(en)
|
2006-10-05 |
2011-05-24 |
Massachusetts Institute Of Technology |
Multifunctional encoded particles for high-throughput analysis
|
DK2092065T4
(da)
|
2006-10-18 |
2019-10-21 |
Ionis Pharmaceuticals Inc |
Antisense-forbindelser
|
EP2090665A2
(de)
|
2006-10-20 |
2009-08-19 |
Exiqon A/S |
Neue humane MikroRNAs im Zusammenhang mit Krebs
|
EP2407558A1
(de)
|
2006-10-31 |
2012-01-18 |
Noxxon Pharma AG |
Verfahren zum Nachweis eines einzel- oder doppelsträngigen Nukleinsäuremoleküls
|
EP2094832B1
(de)
|
2006-11-15 |
2015-04-22 |
The J. David Gladstone Institutes |
Verfahren und zusammensetzungen zur verringerung von amyloid-beta-spiegeln
|
US8084437B2
(en)
|
2006-11-27 |
2011-12-27 |
Isis Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia
|
US8093222B2
(en)
|
2006-11-27 |
2012-01-10 |
Isis Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia
|
US8293684B2
(en)
|
2006-11-29 |
2012-10-23 |
Exiqon |
Locked nucleic acid reagents for labelling nucleic acids
|
EP3536788A1
(de)
|
2006-12-21 |
2019-09-11 |
QIAGEN GmbH |
Mikro-rna-zielortblockierende oligos und verwendungen davon
|
EP2118118B1
(de)
*
|
2007-01-19 |
2017-09-27 |
Exiqon A/S |
Vermittelte zelluläre verabreichung von lna-oligonukleotiden
|
MX2009008470A
(es)
|
2007-02-09 |
2009-11-26 |
Univ Northwestern |
Particulas para detectar objetivos intracelulares.
|
DK2149605T3
(da)
|
2007-03-22 |
2013-09-30 |
Santaris Pharma As |
Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
|
JP2010521193A
(ja)
|
2007-03-22 |
2010-06-24 |
サンタリス ファーマ アー/エス |
Apo−b100発現の阻害のためのrnaアンタゴニスト化合物
|
CN101679979A
(zh)
|
2007-03-24 |
2010-03-24 |
基酶有限公司 |
施用与人载脂蛋白b互补的反义寡核苷酸
|
US8999634B2
(en)
|
2007-04-27 |
2015-04-07 |
Quest Diagnostics Investments Incorporated |
Nucleic acid detection combining amplification with fragmentation
|
CA2687291A1
(en)
|
2007-05-16 |
2008-11-20 |
Ktb Tumorforschungsgesellschaft Mbh |
Low-viscous anthracycline formulation
|
CA2688321A1
(en)
*
|
2007-05-30 |
2008-12-11 |
Isis Pharmaceuticals, Inc. |
N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
|
DK2826863T3
(en)
|
2007-05-30 |
2017-12-04 |
Univ Northwestern |
NUCLEIC ACID FUNCTIONALIZED NANOPARTICLES FOR THERAPEUTIC APPLICATIONS
|
WO2008151023A2
(en)
|
2007-06-01 |
2008-12-11 |
Ibis Biosciences, Inc. |
Methods and compositions for multiple displacement amplification of nucleic acids
|
US7807372B2
(en)
|
2007-06-04 |
2010-10-05 |
Northwestern University |
Screening sequence selectivity of oligonucleotide-binding molecules using nanoparticle based colorimetric assay
|
WO2008153933A2
(en)
|
2007-06-06 |
2008-12-18 |
Avi Biopharma, Inc. |
Soluble her2 and her3 splice variant proteins, splice-switching oligonucleotides, and their use in the treatment of disease
|
ES2376507T5
(es)
†
|
2007-07-05 |
2015-08-31 |
Isis Pharmaceuticals, Inc. |
Análogos de ácidos nucleicos bicíclicos 6-disustituidos
|
US8455190B2
(en)
|
2007-08-01 |
2013-06-04 |
Dana-Farber Cancer Institute, Inc. |
Enrichment of a target sequence
|
WO2009023855A2
(en)
|
2007-08-15 |
2009-02-19 |
Isis Pharmaceuticals, Inc. |
Tetrahydropyran nucleic acid analogs
|
US8299237B2
(en)
|
2007-08-30 |
2012-10-30 |
Hadasit Medical Research Services & Development Ltd. |
Nucleic acid sequences comprising NF-κB binding site within O(6)-methylguanine-DNA-methyltransferase (MGMT) promoter region and uses thereof for the treatment of cancer and immune-related disorders
|
EP2548962B1
(de)
|
2007-09-19 |
2016-01-13 |
Applied Biosystems, LLC |
Sirna-sequenz-unabhängige Modifikationsformate zur Verringerung von das Ziel verfehlenden phänotypischen Effekten bei RNAI und stabilisierte Formen davon
|
EP2205741A2
(de)
|
2007-10-02 |
2010-07-14 |
Amgen Inc. |
ERHÖHUNG DES ERYTHROPOIETINSPIEGELS MITTELS VERWENDUNG VON MIT miRNA HYBRIDISIERBAREN NUKLEINSÄUREN UND VORLÄUFER DAVON
|
JP5646997B2
(ja)
|
2007-10-03 |
2014-12-24 |
クォーク ファーマシューティカルズ インコーポレーティッドQuark Pharmaceuticals,Inc. |
新規siRNA構造
|
MY156951A
(en)
|
2007-10-04 |
2016-04-15 |
Santaris Pharma As |
Micromirs
|
CA2705213C
(en)
|
2007-11-07 |
2016-10-04 |
The University Of British Columbia |
Microfluidic device and method of using same
|
EP2227545A2
(de)
|
2007-11-09 |
2010-09-15 |
Isis Pharmaceuticals, Inc. |
Modulation der expression von faktor 7
|
CN101984759A
(zh)
|
2007-11-09 |
2011-03-09 |
Isis药物公司 |
因子9表达的调节
|
WO2009067628A1
(en)
|
2007-11-20 |
2009-05-28 |
Applied Biosystems Inc. |
Reversible di-nucleotide terminator sequencing
|
US8685675B2
(en)
|
2007-11-27 |
2014-04-01 |
Human Genetic Signatures Pty. Ltd. |
Enzymes for amplification and copying bisulphite modified nucleic acids
|
EP2229583B1
(de)
|
2007-12-06 |
2019-04-10 |
Genalyte Inc. |
Markierungfreies nukleinsäure-synthese-überwachungssystem und verfahren
|
US8361980B2
(en)
|
2008-03-07 |
2013-01-29 |
Santaris Pharma A/S |
Pharmaceutical compositions for treatment of microRNA related diseases
|
US8227431B2
(en)
|
2008-03-17 |
2012-07-24 |
Hetero Drugs Limited |
Nucleoside derivatives
|
WO2009117589A1
(en)
|
2008-03-21 |
2009-09-24 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising tricyclic nucleosides and methods for their use
|
AU2009232355A1
(en)
|
2008-04-04 |
2009-10-08 |
Calando Pharmaceuticals, Inc. |
Compositions and use of EPAS1 inhibitors
|
WO2009124238A1
(en)
|
2008-04-04 |
2009-10-08 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides
|
WO2009124295A2
(en)
|
2008-04-04 |
2009-10-08 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
|
US8278287B2
(en)
|
2008-04-15 |
2012-10-02 |
Quark Pharmaceuticals Inc. |
siRNA compounds for inhibiting NRF2
|
ES2554168T3
(es)
|
2008-04-18 |
2015-12-16 |
Baxter International Inc. |
Composición basada en microesferas para prevenir y/o revertir la diabetes autoinmune de nueva aparición
|
WO2009143387A2
(en)
|
2008-05-22 |
2009-11-26 |
Isis Pharmaceuticals, Inc. |
Modulation of smrt expression
|
WO2009143390A2
(en)
|
2008-05-22 |
2009-11-26 |
Isis Pharmaceuticals, Inc. |
Methods for modulating expression of rbp4
|
EP2285979B2
(de)
|
2008-05-27 |
2020-02-19 |
Dako Denmark A/S |
Hybridisierungszusammensetzungen und -verfahren
|
US8222221B2
(en)
|
2008-06-04 |
2012-07-17 |
The Board Of Regents Of The University Of Texas System |
Modulation of gene expression through endogenous small RNA targeting of gene promoters
|
US8431692B2
(en)
|
2008-06-06 |
2013-04-30 |
Quark Pharmaceuticals, Inc. |
Compositions and methods for treatment of ear disorders
|
WO2010014592A1
(en)
|
2008-07-29 |
2010-02-04 |
The Board Of Regents Of The University Of Texas Sytem |
Selective inhibition of polyglutamine protein expression
|
JP5272230B2
(ja)
*
|
2008-07-30 |
2013-08-28 |
日鉄住金環境株式会社 |
ユニバーサルな核酸プローブセットおよびその使用方法
|
EP2315832B1
(de)
|
2008-08-01 |
2015-04-08 |
Roche Innovation Center Copenhagen A/S |
Micro-rna-vermittelte modulation koloniestimulierender faktoren
|
WO2010021344A1
(ja)
*
|
2008-08-22 |
2010-02-25 |
独立行政法人科学技術振興機構 |
新規核酸誘導体およびそれを用いたヌクレアーゼ耐性核酸の調製方法
|
ES2657696T3
(es)
|
2008-08-25 |
2018-03-06 |
Excaliard Pharmaceuticals, Inc. |
Método para reducir la cicatrización durante la curación de una herida utilizando compuestos antisentido dirigidos al CTGF
|
KR101762734B1
(ko)
|
2008-08-25 |
2017-07-28 |
엑스칼리아드 파마슈티컬즈, 인코포레이티드 |
결합 조직 성장 인자에 대한 안티센스 올리고뉴클레오타이드 및 그의 용도
|
GB2467691A
(en)
|
2008-09-05 |
2010-08-11 |
Aueon Inc |
Methods for stratifying and annotating cancer drug treatment options
|
DK2361256T3
(da)
|
2008-09-24 |
2013-07-01 |
Isis Pharmaceuticals Inc |
Cyclohexenyl-nukleinsyreanaloger
|
EP3335715A3
(de)
|
2008-10-15 |
2018-08-08 |
Ionis Pharmaceuticals, Inc. |
Modulation der faktor-11-expression
|
EP2447274B1
(de)
|
2008-10-24 |
2017-10-04 |
Ionis Pharmaceuticals, Inc. |
Oligomerverbindungen und Verfahren
|
WO2010048549A2
(en)
|
2008-10-24 |
2010-04-29 |
Isis Pharmaceuticals, Inc. |
5' and 2' bis-substituted nucleosides and oligomeric compounds prepared therefrom
|
US9846126B2
(en)
|
2008-10-27 |
2017-12-19 |
Genalyte, Inc. |
Biosensors based on optical probing and sensing
|
CA2744207C
(en)
|
2008-11-24 |
2019-05-28 |
Northwestern University |
Polyvalent rna-nanoparticle compositions
|
CN102317458B
(zh)
|
2008-12-04 |
2018-01-02 |
库尔纳公司 |
通过红细胞生成素(epo)天然反义转录物的抑制对epo相关疾病的治疗
|
EP2370581B1
(de)
|
2008-12-04 |
2016-08-03 |
CuRNA, Inc. |
Behandlung von erkrankungen im zusammenhang mit dem vaskulären endothelialen wachstumsfaktor (vegf) mittels hemmung des natürlichen antisense-transkripts gegen vegf
|
KR101866152B1
(ko)
|
2008-12-04 |
2018-06-08 |
큐알엔에이, 인크. |
종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
|
US20110288155A1
(en)
|
2008-12-18 |
2011-11-24 |
Elena Feinstein |
Sirna compounds and methods of use thereof
|
WO2010074562A1
(en)
|
2008-12-22 |
2010-07-01 |
Keygene N.V. |
Use of double stranded rna to increase the efficiency of targeted gene alteration in plant protoplasts
|
US20100233270A1
(en)
|
2009-01-08 |
2010-09-16 |
Northwestern University |
Delivery of Oligonucleotide-Functionalized Nanoparticles
|
US8680254B2
(en)
|
2009-01-14 |
2014-03-25 |
Philadelphia Health & Education Corporation |
Modulation of pre-mRNA using splice modulating oligonucleotides as therapeutic agents in the treatment of disease
|
JP5749656B2
(ja)
|
2009-02-02 |
2015-07-15 |
エクシコン エ/エス |
低分子rna種の定量化のための方法
|
WO2010091308A2
(en)
|
2009-02-06 |
2010-08-12 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and methods
|
WO2010090969A1
(en)
|
2009-02-06 |
2010-08-12 |
Isis Pharmaceuticals, Inc. |
Tetrahydropyran nucleic acid analogs
|
HUE026280T2
(en)
|
2009-02-12 |
2016-06-28 |
Curna Inc |
Treatment of brain-derived neurotrophic factor (BDNF) -related diseases by inhibition of natural antisense transcripts associated with BDNF \ t
|
US9303287B2
(en)
|
2009-02-26 |
2016-04-05 |
Dako Denmark A/S |
Compositions and methods for RNA hybridization applications
|
US9107933B2
(en)
|
2009-03-16 |
2015-08-18 |
Isis Pharmaceuticals, Inc. |
Compositions and methods of targeting apolipoprotein B for the reduction of apolipoprotein C-III
|
WO2010107733A2
(en)
|
2009-03-16 |
2010-09-23 |
Curna, Inc. |
Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
|
JP5904935B2
(ja)
|
2009-03-17 |
2016-04-20 |
クルナ・インコーポレーテッド |
デルタ様1ホモログ(dlk1)に対する天然アンチセンス転写物の抑制によるdlk1関連疾患の治療
|
WO2010120511A2
(en)
|
2009-03-31 |
2010-10-21 |
Altair Therapeutics, Inc. |
Method of treating respiratory disorders
|
CN102449170A
(zh)
|
2009-04-15 |
2012-05-09 |
西北大学 |
寡核苷酸功能化的纳米颗粒的递送
|
EP3524275A1
(de)
|
2009-04-22 |
2019-08-14 |
Massachusetts Institute Of Technology |
Angeborene immununterdrückung ermöglicht die wiederholte verabreichung von langen rna-molekülen
|
EP2421972A2
(de)
|
2009-04-24 |
2012-02-29 |
The Board of Regents of The University of Texas System |
Modulation der genexpression mit auf genregionen nach 3-untranslatierten regionen gerichteten oligomeren
|
JP5773535B2
(ja)
|
2009-04-24 |
2015-09-02 |
ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブRoche Innovation Center Copenhagen A/S |
インターフェロンに非応答性のhcv患者の治療のための医薬組成物
|
CA2761152A1
(en)
|
2009-05-06 |
2010-11-11 |
Opko Curna, Llc |
Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene
|
ES2609655T3
(es)
|
2009-05-06 |
2017-04-21 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con tristetraprolina (TTP) mediante inhibición de transcrito antisentido natural para TTP
|
KR101742334B1
(ko)
|
2009-05-08 |
2017-06-01 |
큐알엔에이, 인크. |
Dmd 패밀리에 대한 천연 안티센스 전사체의 억제에 의한 디스트로핀 패밀리 관련된 질환의 치료
|
US8957037B2
(en)
|
2009-05-18 |
2015-02-17 |
Curna, Inc. |
Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
|
EP3597657B1
(de)
|
2009-05-21 |
2021-09-01 |
Siemens Healthcare Diagnostics Inc. |
Universaletiketten mit nichtnatürlichen nukleobasen
|
CN102549158B
(zh)
|
2009-05-22 |
2017-09-26 |
库尔纳公司 |
通过抑制针对转录因子e3(tfe3)的天然反义转录物来治疗tfe3和胰岛素受体底物蛋白2(irs2)相关的疾病
|
EP2435571B1
(de)
|
2009-05-28 |
2016-12-14 |
CuRNA, Inc. |
Behandlung von durch antivirale gene bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen ein antivirales gen
|
CN102458418B
(zh)
|
2009-06-08 |
2015-09-16 |
夸克制药公司 |
一种寡核苷酸化合物的制药用途
|
KR101702689B1
(ko)
|
2009-06-16 |
2017-02-06 |
큐알엔에이, 인크. |
Pon1에 대한 천연 안티센스 전사체의 억제에 의한 파라옥소나제 1(pon1) 관련된 질환의 치료
|
CN102695797B
(zh)
|
2009-06-16 |
2018-05-25 |
库尔纳公司 |
通过抑制针对胶原基因的天然反义转录物来治疗胶原基因相关的疾病
|
CA2765889A1
(en)
|
2009-06-24 |
2010-12-29 |
Opko Curna, Llc |
Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
|
EP2446037B1
(de)
|
2009-06-26 |
2016-04-20 |
CuRNA, Inc. |
Behandlung von krankheiten im zusammenhang mit dem down-syndrom-gen durch hemmung des natürlichen antisense-transkripts zu einem down-syndrom-gen
|
US8563528B2
(en)
|
2009-07-21 |
2013-10-22 |
Santaris Pharma A/S |
Antisense oligomers targeting PCSK9
|
JP2011024434A
(ja)
|
2009-07-22 |
2011-02-10 |
Galaxy Pharma Inc |
オリゴヌクレオチドのスクリーニング方法及びオリゴヌクレオチドライブラリー
|
CN102712925B
(zh)
|
2009-07-24 |
2017-10-27 |
库尔纳公司 |
通过抑制sirtuin(sirt)的天然反义转录物来治疗sirtuin(sirt)相关性疾病
|
WO2011012136A1
(en)
|
2009-07-28 |
2011-02-03 |
Exiqon A/S |
A method for classifying a human cell sample as cancerous
|
CN102762731B
(zh)
|
2009-08-05 |
2018-06-22 |
库尔纳公司 |
通过抑制针对胰岛素基因(ins)的天然反义转录物来治疗胰岛素基因(ins)相关的疾病
|
EP2462153B1
(de)
|
2009-08-06 |
2015-07-29 |
Isis Pharmaceuticals, Inc. |
Bicyclische cyclohexosenukleinsäureanaloga
|
EP2464731B1
(de)
|
2009-08-11 |
2016-10-05 |
CuRNA, Inc. |
Behandlung von adiponectin (adipoq)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen ein adiponectin (adipoq)
|
CA2771228C
(en)
|
2009-08-21 |
2020-12-29 |
Opko Curna, Llc |
Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip
|
US9023822B2
(en)
|
2009-08-25 |
2015-05-05 |
Curna, Inc. |
Treatment of 'IQ motif containing GTPase activating protein' (IQGAP) related diseases by inhibition of natural antisense transcript to IQGAP
|
ES2599076T3
(es)
|
2009-09-02 |
2017-01-31 |
Genentech, Inc. |
Smoothened mutante y métodos de utilización del mismo
|
CA2931725C
(en)
|
2009-09-11 |
2021-10-19 |
Ionis Pharmaceuticals, Inc. |
Modulation of huntingtin expression
|
EP2480669B1
(de)
|
2009-09-25 |
2017-11-08 |
CuRNA, Inc. |
Behandlung filaggrin (flg)-assoziierter erkrankungen durch modulierung der flg-expression und -aktivität
|
EP2488656B1
(de)
|
2009-10-15 |
2015-06-03 |
Ibis Biosciences, Inc. |
Mehrfache verschiebungsverstärkung
|
BR112012009409A2
(pt)
|
2009-10-22 |
2017-02-21 |
Genentech Inc |
método de identificação de uma substância inibidora, molécula antagonista, ácido nucleico isolado, vetor, célula hospedeira, método para fabricar a molécula, composição, artigo de fabricação, método de inibição de uma atividade biológica, método de tratamento de uma condição patológica, método para detectar msp em uma amostra e método para detectar hepsina em uma amostra
|
CA2778532A1
(en)
|
2009-10-27 |
2011-05-12 |
Swift Biosciences, Inc. |
Polynucleotide primers and probes
|
CA2779099C
(en)
|
2009-10-30 |
2021-08-10 |
Northwestern University |
Templated nanoconjugates
|
US20110110860A1
(en)
|
2009-11-02 |
2011-05-12 |
The Board Of Regents Of The University Of Texas System |
Modulation of ldl receptor gene expression with double-stranded rnas targeting the ldl receptor gene promoter
|
EP2496716A1
(de)
|
2009-11-03 |
2012-09-12 |
University Of Virginia Patent Foundation |
Vielseitiges sichtbares verfahren für den nachweis von polymeranalyten
|
US8916362B2
(en)
|
2009-11-23 |
2014-12-23 |
Swift Biosciences, Inc. |
Devices comprising a polynucleotide to extend single stranded target molecules
|
TWI507524B
(zh)
|
2009-11-30 |
2015-11-11 |
Genentech Inc |
診斷及治療腫瘤之組合物及方法
|
CA2781907C
(en)
|
2009-12-02 |
2019-07-16 |
Dako Denmark A/S |
Compositions and methods for performing hybridizations with no denaturation
|
AU2010328104B2
(en)
|
2009-12-09 |
2014-10-30 |
Nitto Denko Corporation |
Modulation of hsp47 expression
|
US8778904B2
(en)
|
2009-12-09 |
2014-07-15 |
Quark Pharmaceuticals, Inc. |
Methods and compositions for treating diseases, disorders or injury of the CNS
|
CN102712927B
(zh)
|
2009-12-16 |
2017-12-01 |
库尔纳公司 |
通过抑制膜结合转录因子肽酶,位点1(mbtps1)的天然反义转录物来治疗mbtps1相关疾病
|
CN102781480B
(zh)
|
2009-12-23 |
2018-07-27 |
库尔纳公司 |
通过抑制解偶联蛋白2(ucp2)的天然反义转录物而治疗ucp2相关疾病
|
CN102869776B
(zh)
|
2009-12-23 |
2017-06-23 |
库尔纳公司 |
通过抑制肝细胞生长因子(hgf)的天然反义转录物而治疗hgf相关疾病
|
EP2519633B1
(de)
|
2009-12-29 |
2017-10-25 |
CuRNA, Inc. |
Behandlung von erkrankungen im zusammenhang mit dem nuclear-respirator-faktor 1 (nrf1) mittels hemmung des natürlichen antisense-transkripts gegen nrf1
|
CN102770540B
(zh)
|
2009-12-29 |
2017-06-23 |
库尔纳公司 |
通过抑制肿瘤蛋白63(p63)的天然反义转录物而治疗p63相关疾病
|
JP6083735B2
(ja)
|
2009-12-31 |
2017-02-22 |
カッパーアールエヌエー,インコーポレイテッド |
インスリン受容体基質2(irs2)および転写因子3(tfe3)に対する天然アンチセンス転写物の阻害によるインスリン受容体基質2(irs2)関連疾患の治療
|
CN102906264B
(zh)
|
2010-01-04 |
2017-08-04 |
库尔纳公司 |
通过抑制干扰素调节因子8(irf8)的天然反义转录物而治疗irf8相关疾病
|
CN102822342B
(zh)
|
2010-01-06 |
2017-05-10 |
库尔纳公司 |
通过抑制胰腺发育基因的天然反义转录物而治疗胰腺发育基因相关疾病
|
WO2011084193A1
(en)
|
2010-01-07 |
2011-07-14 |
Quark Pharmaceuticals, Inc. |
Oligonucleotide compounds comprising non-nucleotide overhangs
|
ES2677969T3
(es)
|
2010-01-08 |
2018-08-07 |
Ionis Pharmaceuticals, Inc. |
Modulación de la expresión tipo angiopoyetina 3
|
JP6027893B2
(ja)
|
2010-01-11 |
2016-11-16 |
カッパーアールエヌエー,インコーポレイテッド |
性ホルモン結合グロブリン(shbg)に対する天然アンチセンス転写物の阻害による性ホルモン結合グロブリン(shbg)関連疾患の治療
|
US8779118B2
(en)
|
2010-01-11 |
2014-07-15 |
Isis Pharmaceuticals, Inc. |
Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
|
NO2529015T3
(de)
|
2010-01-25 |
2018-04-14 |
|
|
WO2011097388A1
(en)
|
2010-02-03 |
2011-08-11 |
Alnylam Pharmaceuticals, Inc. |
Selective inhibition of polyglutamine protein expression
|
WO2011097643A1
(en)
|
2010-02-08 |
2011-08-11 |
Isis Pharmaceuticals, Inc. |
Selective reduction of allelic variants
|
JP6018506B2
(ja)
|
2010-02-08 |
2016-11-02 |
アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. |
対立遺伝子多様体の選択的低減
|
US8962586B2
(en)
|
2010-02-22 |
2015-02-24 |
Curna, Inc. |
Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcript to PYCR1
|
WO2011105902A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 8-beta (c8-beta) and uses thereof
|
WO2011105901A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 9 (c9) and uses thereof
|
WO2011105900A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
|
WO2011106297A2
(en)
|
2010-02-23 |
2011-09-01 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
EP2542678B1
(de)
|
2010-03-04 |
2017-04-12 |
InteRNA Technologies B.V. |
Mirna-molekül, das durch seine quelle definiert ist, und seine therapeutischen verwendungen bei emt assoziierten krebs
|
DK2545189T3
(en)
|
2010-03-08 |
2018-04-23 |
Dana Farber Cancer Inst Inc |
COMPLETE COLD-PCR ENRICHMENT WITH REFERENCE BLOCKING SEQUENCE
|
US20130101512A1
(en)
|
2010-03-12 |
2013-04-25 |
Chad A. Mirkin |
Crosslinked polynucleotide structure
|
WO2011115817A1
(en)
|
2010-03-16 |
2011-09-22 |
Isis Pharmaceuticals, Inc. |
Methods of preparing 2'-o-substituted purine nucleosides
|
WO2011115818A1
(en)
|
2010-03-17 |
2011-09-22 |
Isis Pharmaceuticals, Inc. |
5'-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
|
WO2011120049A1
(en)
|
2010-03-26 |
2011-09-29 |
Integrated Dna Technologies, Inc. |
Methods for enhancing nucleic acid hybridization
|
US8889350B2
(en)
|
2010-03-26 |
2014-11-18 |
Swift Biosciences, Inc. |
Methods and compositions for isolating polynucleotides
|
US9506057B2
(en)
|
2010-03-26 |
2016-11-29 |
Integrated Dna Technologies, Inc. |
Modifications for antisense compounds
|
EP2553098B1
(de)
|
2010-04-02 |
2017-10-11 |
CuRNA, Inc. |
Behandlung von durch den koloniestimulierenden faktor 3 (csf3) vermittelten erkrankungen durch hemmung des natürlichen antisense-transkripts für csf3
|
KR101900962B1
(ko)
|
2010-04-09 |
2018-09-20 |
큐알엔에이, 인크. |
섬유아세포 성장 인자 21 (fgf21)에 대한 자연 안티센스 전사체의 저해에 의한 섬유아세포 성장 인자 21 (fgf21) 관련된 질환의 치료
|
US20110269194A1
(en)
|
2010-04-20 |
2011-11-03 |
Swift Biosciences, Inc. |
Materials and methods for nucleic acid fractionation by solid phase entrapment and enzyme-mediated detachment
|
CN103154014B
(zh)
|
2010-04-28 |
2015-03-25 |
Isis制药公司 |
修饰核苷、其类似物以及由它们制备的寡聚化合物
|
WO2011139695A2
(en)
|
2010-04-28 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
Modified 5' diphosphate nucleosides and oligomeric compounds prepared therefrom
|
US9127033B2
(en)
|
2010-04-28 |
2015-09-08 |
Isis Pharmaceuticals, Inc. |
5′ modified nucleosides and oligomeric compounds prepared therefrom
|
WO2011139911A2
(en)
|
2010-04-29 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
Lipid formulated single stranded rna
|
WO2011139917A1
(en)
|
2010-04-29 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
Modulation of transthyretin expression
|
US9212390B2
(en)
|
2010-04-30 |
2015-12-15 |
Exiqon A/S |
In situ hybridization method and buffer
|
CA2798218A1
(en)
|
2010-05-03 |
2011-11-10 |
Curna, Inc. |
Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
|
CN102958941A
(zh)
|
2010-05-03 |
2013-03-06 |
霍夫曼-拉罗奇有限公司 |
用于肿瘤诊断和治疗的组合物和方法
|
TWI531370B
(zh)
|
2010-05-14 |
2016-05-01 |
可娜公司 |
藉由抑制par4天然反股轉錄本治療par4相關疾病
|
US8980858B2
(en)
|
2010-05-26 |
2015-03-17 |
Curna, Inc. |
Treatment of methionine sulfoxide reductase a (MSRA) related diseases by inhibition of natural antisense transcript to MSRA
|
NO2576783T3
(de)
|
2010-05-26 |
2018-04-28 |
|
|
WO2011150226A1
(en)
|
2010-05-26 |
2011-12-01 |
Landers James P |
Method for detecting nucleic acids based on aggregate formation
|
WO2011156278A1
(en)
|
2010-06-07 |
2011-12-15 |
Isis Pharmaceuticals, Inc. |
Bicyclic nucleosides and oligomeric compounds prepared therefrom
|
EP2576839B1
(de)
|
2010-06-07 |
2017-05-10 |
Firefly Bioworks, Inc. |
Nukleinsäurenachweis und -quantifizierung durch posthybridisierungs-kennzeichnung und universelle kodierung
|
US8846637B2
(en)
|
2010-06-08 |
2014-09-30 |
Isis Pharmaceuticals, Inc. |
Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
|
EP2582397A4
(de)
|
2010-06-15 |
2014-10-29 |
Isis Pharmaceuticals Inc |
Verbindungen und verfahren zur modulierung der interaktion zwischen proteinen und zielnukleinsäuren
|
WO2011163499A2
(en)
|
2010-06-23 |
2011-12-29 |
Opko Curna, Llc |
Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna
|
KR20130123364A
(ko)
|
2010-06-30 |
2013-11-12 |
미쓰비시 가가쿠 메디엔스 가부시키가이샤 |
고감도 변이 유전자 검출 방법
|
CA2804599C
(en)
|
2010-07-06 |
2023-01-31 |
Interna Technologies Bv |
Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
|
ES2663598T3
(es)
|
2010-07-14 |
2018-04-16 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con el homólogo de discos grandes (dlg) mediante la inhibición del transcrito antisentido natural a dlg
|
ES2655500T3
(es)
|
2010-07-16 |
2018-02-20 |
Tocagen Inc. |
Detección de retrovirus
|
WO2012012443A2
(en)
|
2010-07-19 |
2012-01-26 |
Bennett C Frank |
Modulation of dystrophia myotonica-protein kinase (dmpk) expression
|
GB201012418D0
(en)
|
2010-07-23 |
2010-09-08 |
Santaris Pharma As |
Process
|
JP6106085B2
(ja)
|
2010-08-24 |
2017-03-29 |
サーナ・セラピューティクス・インコーポレイテッドSirna Therapeutics,Inc. |
内部非核酸スペーサーを含む一本鎖RNAi剤
|
EP2896696B1
(de)
|
2010-09-07 |
2017-12-27 |
Integrated Dna Technologies, Inc. |
Modifikationen für Antisense-Verbindungen
|
ES2701020T3
(es)
|
2010-09-22 |
2019-02-20 |
Alios Biopharma Inc |
Nucleósidos azido y análogos nucleotídicos
|
ES2588981T3
(es)
|
2010-10-05 |
2016-11-08 |
Genentech, Inc. |
Smoothened mutante y métodos de uso de la misma
|
KR101886457B1
(ko)
|
2010-10-06 |
2018-08-07 |
큐알엔에이, 인크. |
시알리다아제 4 (neu4)에 대한 자연 안티센스 전사체의 저해에 의한 neu4 관련된 질환의 치료
|
US8648053B2
(en)
|
2010-10-20 |
2014-02-11 |
Rosalind Franklin University Of Medicine And Science |
Antisense oligonucleotides that target a cryptic splice site in Ush1c as a therapeutic for Usher syndrome
|
EP2630241B1
(de)
|
2010-10-22 |
2018-10-17 |
CuRNA, Inc. |
Behandlung von alpha-l-iduronidase (idua)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen idua
|
DK2632472T3
(en)
|
2010-10-29 |
2018-03-19 |
Sirna Therapeutics Inc |
RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
|
WO2012061778A2
(en)
|
2010-11-05 |
2012-05-10 |
Genalyte, Inc. |
Optical analyte detection systems and methods of use
|
WO2012064758A2
(en)
|
2010-11-08 |
2012-05-18 |
Isis Pharmaceuticals, Inc. |
Methods for modulating factor 12 expression
|
JP6126009B2
(ja)
*
|
2010-11-17 |
2017-05-10 |
アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. |
α−シヌクレイン発現の調節
|
WO2012068340A2
(en)
|
2010-11-18 |
2012-05-24 |
Opko Curna Llc |
Antagonat compositions and methods of use
|
KR102010598B1
(ko)
|
2010-11-23 |
2019-08-13 |
큐알엔에이, 인크. |
Nanog에 대한 자연 안티센스 전사체의 저해에 의한 nanog 관련된 질환의 치료
|
AU2011337323B2
(en)
|
2010-12-02 |
2015-11-26 |
Keygene N.V. |
Targeted alteration of DNA
|
US9518258B2
(en)
|
2010-12-02 |
2016-12-13 |
Keygene N.V. |
Targeted alteration of DNA with oligonucleotides
|
MX2017015093A
(es)
|
2011-01-11 |
2023-03-10 |
Seegene Inc |
Detección de secuencias de ácido nucleico objetivo mediante ensayo de escisión y extensión del pto.
|
EP2474617A1
(de)
|
2011-01-11 |
2012-07-11 |
InteRNA Technologies BV |
MIR zur Behandlung von Neoangiogenese
|
US20130338178A1
(en)
|
2011-02-02 |
2013-12-19 |
The Trustees Of Princeton University |
Sirtuin modulators as inhibitors of cytomegalovirus
|
CA2825059A1
(en)
|
2011-02-02 |
2012-08-09 |
Excaliard Pharmaceuticals, Inc. |
Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (ctgf)
|
EP3067421B1
(de)
|
2011-02-08 |
2018-10-10 |
Ionis Pharmaceuticals, Inc. |
Oligomere verbindungen mit bicyclischen nukleotiden und verwendungen davon
|
WO2012109495A1
(en)
|
2011-02-09 |
2012-08-16 |
Metabolic Solutions Development Company, Llc |
Cellular targets of thiazolidinediones
|
WO2012113775A1
(en)
|
2011-02-21 |
2012-08-30 |
University Of Zurich |
Ankyrin g and modulators thereof for the treatment of neurodegenerative disorders
|
SG193280A1
(en)
|
2011-03-03 |
2013-10-30 |
Quark Pharmaceuticals Inc |
Oligonucleotide modulators of the toll-like receptor pathway
|
US9796979B2
(en)
|
2011-03-03 |
2017-10-24 |
Quark Pharmaceuticals Inc. |
Oligonucleotide modulators of the toll-like receptor pathway
|
CA2828002A1
(en)
|
2011-03-03 |
2012-09-07 |
Quark Pharmaceuticals, Inc. |
Compositions and methods for treating lung disease and injury
|
EP2495336B8
(de)
|
2011-03-04 |
2014-07-23 |
Roche Diagnostics GmbH |
Neuer Typ von universellen Sonden zur Detektion von Genomvarianten
|
JP5852222B2
(ja)
|
2011-03-29 |
2016-02-03 |
シージーン アイエヌシー |
Pto切断及び延長−依存的切断によるターゲット核酸配列の検出
|
WO2012135664A2
(en)
|
2011-03-31 |
2012-10-04 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions to enable multiplex cold-pcr
|
PL2697243T3
(pl)
|
2011-04-01 |
2019-05-31 |
Ionis Pharmaceuticals Inc |
Modulacja ekspresji przekaźnika sygnału i aktywatora transkrypcji 3 (stat3)
|
EP2508607A1
(de)
|
2011-04-07 |
2012-10-10 |
Helmholtz-Zentrum für Infektionsforschung GmbH |
Medikament zur Leberregeneration und zur Behandlung von Leberversagen
|
EP2697244B1
(de)
|
2011-04-13 |
2017-05-17 |
Ionis Pharmaceuticals, Inc. |
Antisense-modulation der ptp18-expression
|
RS61447B1
(sr)
|
2011-04-21 |
2021-03-31 |
Glaxo Group Ltd |
Modulacija ekspresije virusa hepatitisa b (hbv)
|
WO2012149154A1
(en)
|
2011-04-26 |
2012-11-01 |
Swift Biosciences, Inc. |
Polynucleotide primers and probes
|
CN107854478A
(zh)
|
2011-04-27 |
2018-03-30 |
Ionis制药公司 |
载脂蛋白ciii(apociii)表达的调节
|
CA2834218C
(en)
|
2011-04-29 |
2021-02-16 |
Sequenom, Inc. |
Quantification of a minority nucleic acid species using inhibitory oligonucleotides
|
WO2012151324A1
(en)
|
2011-05-02 |
2012-11-08 |
Isis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with usher syndrome
|
WO2012151289A2
(en)
|
2011-05-02 |
2012-11-08 |
University Of Virginia Patent Foundation |
Method and system to detect aggregate formation on a substrate
|
WO2012151268A1
(en)
|
2011-05-02 |
2012-11-08 |
University Of Virginia Patent Foundation |
Method and system for high throughput optical and label free detection of analytes
|
WO2012150749A1
(en)
|
2011-05-04 |
2012-11-08 |
Seegene, Inc. |
Detection of target nucleic acid sequences by po cleavage and hybridization
|
US10196637B2
(en)
|
2011-06-08 |
2019-02-05 |
Nitto Denko Corporation |
Retinoid-lipid drug carrier
|
TWI658830B
(zh)
|
2011-06-08 |
2019-05-11 |
日東電工股份有限公司 |
Hsp47表現調控強化用類視色素脂質體
|
US9593330B2
(en)
|
2011-06-09 |
2017-03-14 |
Curna, Inc. |
Treatment of frataxin (FXN) related diseases by inhibition of natural antisense transcript to FXN
|
WO2012170347A1
(en)
|
2011-06-09 |
2012-12-13 |
Isis Pharmaceuticals, Inc. |
Bicyclic nucleosides and oligomeric compounds prepared therefrom
|
AU2012267546B2
(en)
|
2011-06-10 |
2015-12-24 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating kallikrein (KLKB1) expression
|
US9187749B2
(en)
|
2011-06-10 |
2015-11-17 |
Isis Pharmaceuticals, Inc. |
Methods for modulating factor 12 expression
|
WO2012174476A2
(en)
|
2011-06-16 |
2012-12-20 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of fibroblast growth factor receptor 4 expression
|
EP2726153B1
(de)
|
2011-06-29 |
2018-03-28 |
Ionis Pharmaceuticals, Inc. |
Verfahren zur modulierung der kallikrein (klkb1)-expression
|
EP2742056B2
(de)
|
2011-08-11 |
2020-06-10 |
Ionis Pharmaceuticals, Inc. |
Selektive antisense-verbindungen und ihre verwendungen
|
EP2751269B1
(de)
|
2011-08-29 |
2016-03-23 |
Ionis Pharmaceuticals, Inc. |
Verfahren und verbindungen für erkrankungen im zusammenhang mit repeat-expansion
|
US10023861B2
(en)
|
2011-08-29 |
2018-07-17 |
Ionis Pharmaceuticals, Inc. |
Oligomer-conjugate complexes and their use
|
US9650421B2
(en)
|
2011-09-02 |
2017-05-16 |
Northwestern University |
Self-assembled nanostructures
|
WO2013036403A1
(en)
|
2011-09-06 |
2013-03-14 |
Curna, Inc. |
TREATMENT OF DISEASES RELATED TO ALPHA SUBUNITS OF SODIUM CHANNELS, VOLTAGE-GATED (SCNxA) WITH SMALL MOLECULES
|
ES2613743T3
(es)
|
2011-09-07 |
2017-05-25 |
Human Genetic Signatures Pty Ltd |
Ensayo de detección molecular
|
ES2856091T3
(es)
|
2011-09-14 |
2021-09-27 |
Univ Northwestern |
Nanoconjugados capaces de atravesar la barrera hematoencefálica
|
EP2758533B1
(de)
|
2011-09-20 |
2018-04-11 |
Ionis Pharmaceuticals, Inc. |
Antisense-modulation der gcgr-expression
|
EP2761028A1
(de)
|
2011-09-30 |
2014-08-06 |
Dako Denmark A/S |
Hybridisierungszusammensetzungen und -verfahren mit formamid
|
EP2768974B1
(de)
|
2011-10-21 |
2017-07-19 |
Dako Denmark A/S |
Hybridisierungszusammensetzungen und -verfahren
|
RU2014119787A
(ru)
|
2011-10-25 |
2015-12-10 |
Айсис Фармасьютикалс, Инк. |
Антисмысловая регуляция экспрессии gccr
|
WO2013067076A2
(en)
|
2011-11-03 |
2013-05-10 |
Quark Pharmaceuticals, Inc. |
Methods and compositions for neuroprotection
|
US9725722B2
(en)
|
2011-11-07 |
2017-08-08 |
Ionis Pharmaceuticals, Inc. |
Modulation of TMPRSS6 expression
|
US9243291B1
(en)
|
2011-12-01 |
2016-01-26 |
Isis Pharmaceuticals, Inc. |
Methods of predicting toxicity
|
EP2790736B1
(de)
|
2011-12-12 |
2018-01-31 |
Oncoimmunin, Inc. |
In-vivo-verabreichung von oligonucleotiden
|
CA2859581C
(en)
|
2011-12-16 |
2022-03-22 |
National University Corporation Tokyo Medical And Dental University |
Chimeric double-stranded nucleic acid
|
ES2886147T3
(es)
|
2011-12-22 |
2021-12-16 |
Interna Tech B V |
MiARN para el tratamiento del cáncer de cabeza y de cuello
|
SG11201402826YA
(en)
*
|
2011-12-22 |
2014-12-30 |
Alios Biopharma Inc |
Substituted nucleosides, nucleotides and analogs thereof
|
CA2859729C
(en)
|
2011-12-22 |
2021-03-09 |
Isis Pharmaceuticals, Inc. |
Methods for modulating metastasis-associated-in-lung-adenocarcinoma-transcript-1(malat-1) expression
|
US9562072B2
(en)
|
2011-12-27 |
2017-02-07 |
The J. David Gladstone Institutes |
Compositions and methods for regulating glucose metabolism
|
ES2842938T3
(es)
|
2012-01-11 |
2021-07-15 |
Ionis Pharmaceuticals Inc |
Composiciones y métodos para la modulación del empalme de IKBKAP
|
WO2013120003A1
(en)
|
2012-02-08 |
2013-08-15 |
Isis Pharmaceuticals, Inc. |
Modulation of rna by repeat targeting
|
CN104245959B
(zh)
|
2012-03-05 |
2017-10-13 |
Seegene株式会社 |
基于探测和标记寡核苷酸切割及延伸试验的从靶核酸序列的核苷酸变异检测
|
EP3907506A1
(de)
|
2012-03-12 |
2021-11-10 |
The Board of Trustees of the University of Illinois |
Optische analytdetektionssysteme mit magnetischer verstärkung und verfahren zu deren verwendung
|
CN104395480B
(zh)
|
2012-03-13 |
2018-01-30 |
斯威夫特生物科学公司 |
用于通过核酸聚合酶对衬底多核苷酸进行大小受控的同聚物加尾的方法和组合物
|
HUE040179T2
(hu)
|
2012-03-15 |
2019-02-28 |
Curna Inc |
Agyi eredetû neutrotróf faktorral (Brain-derived neurotrophic factor, BDNF) összefüggõ betegségek kezelése a BDNF-fel kapcsolatos természetes antiszensz transzkriptumok gátlása révén
|
WO2013142514A1
(en)
|
2012-03-19 |
2013-09-26 |
Isis Pharmaceuticals, Inc. |
Methods and compositions for modulating alpha-1-antitrypsin expression
|
US9441007B2
(en)
|
2012-03-21 |
2016-09-13 |
Alios Biopharma, Inc. |
Substituted nucleosides, nucleotides and analogs thereof
|
USRE48171E1
(en)
|
2012-03-21 |
2020-08-25 |
Janssen Biopharma, Inc. |
Substituted nucleosides, nucleotides and analogs thereof
|
WO2013148260A1
(en)
|
2012-03-30 |
2013-10-03 |
Washington University |
Methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome
|
EP2850092B1
(de)
|
2012-04-09 |
2017-03-01 |
Ionis Pharmaceuticals, Inc. |
Tricyclische nukleinsäureanaloga
|
WO2013154799A1
(en)
|
2012-04-09 |
2013-10-17 |
Isis Pharmaceuticals, Inc. |
Tricyclic nucleosides and oligomeric compounds prepared therefrom
|
EP2839006B1
(de)
|
2012-04-20 |
2018-01-03 |
Ionis Pharmaceuticals, Inc. |
Oligomere verbindungen mit bicyclischen nukleotiden und verwendungen davon
|
US9133490B2
(en)
|
2012-05-16 |
2015-09-15 |
Transgenomic, Inc. |
Step-up method for COLD-PCR enrichment
|
WO2013173789A2
(en)
|
2012-05-17 |
2013-11-21 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide compositions
|
US9574193B2
(en)
|
2012-05-17 |
2017-02-21 |
Ionis Pharmaceuticals, Inc. |
Methods and compositions for modulating apolipoprotein (a) expression
|
WO2013177468A2
(en)
|
2012-05-24 |
2013-11-28 |
Isis Pharmaceuticals, Inc. |
Methods and compositions for modulating apolipoprotein(a) expression
|
EP2852606B1
(de)
|
2012-05-22 |
2019-08-07 |
Ionis Pharmaceuticals, Inc. |
Modulation der durch verstärker-rns vermittelten genexpression
|
DK2800811T3
(en)
|
2012-05-25 |
2017-07-17 |
Univ Vienna |
METHODS AND COMPOSITIONS FOR RNA DIRECTIVE TARGET DNA MODIFICATION AND FOR RNA DIRECTIVE MODULATION OF TRANSCRIPTION
|
EA027929B1
(ru)
|
2012-05-25 |
2017-09-29 |
Янссен Сайенсиз Айрлэнд Юси |
Нуклеозиды на основе урацила и спирооксетана
|
WO2013181666A2
(en)
|
2012-06-01 |
2013-12-05 |
Isis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with fibronectin
|
WO2013181665A1
(en)
|
2012-06-01 |
2013-12-05 |
Isis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with fibronectin
|
DK3461895T3
(da)
|
2012-06-25 |
2020-07-20 |
Ionis Pharmaceuticals Inc |
Modulation af ube3a-ats-ekspression
|
EP2875131B1
(de)
|
2012-07-18 |
2018-03-14 |
Siemens Healthcare Diagnostics Inc. |
Verfahren zur normalisierung von biologischen proben
|
EP2877579B1
(de)
|
2012-07-27 |
2019-12-18 |
Ionis Pharmaceuticals, Inc. |
Modulation von mit dem reninangiotensinsystem (ras) assoziierten erkrankungen durch angiotensinogen
|
KR102237882B1
(ko)
|
2012-08-15 |
2021-04-07 |
아이오니스 파마수티컬즈, 인코포레이티드 |
변형된 캡핑 프로토콜을 이용하는 올리고머 화합물 제조 방법
|
ES2671478T3
(es)
|
2012-08-31 |
2018-06-06 |
Novartis Ag |
Derivados de 2'-etinil nucleósidos para el tratamiento de infecciones virales
|
HUE039676T2
(hu)
|
2012-09-06 |
2019-01-28 |
Univ Chicago |
Antiszensz polinukleotidok exon-ugrás indukálására és eljárások disztrófiák kezelésére
|
WO2014045126A2
(en)
|
2012-09-18 |
2014-03-27 |
Uti Limited Partnership |
Treatment of pain by inhibition of usp5 de-ubiquitinase
|
AR092982A1
(es)
|
2012-10-11 |
2015-05-13 |
Isis Pharmaceuticals Inc |
Modulacion de la expresion de receptores androgenicos
|
US9523094B2
(en)
|
2012-10-11 |
2016-12-20 |
Ionis Pharmaceuticals, Inc. |
Methods of treating kennedy's disease
|
EP2906699A4
(de)
|
2012-10-11 |
2016-06-08 |
Ionis Pharmaceuticals Inc |
Oligomere verbindungen mit bicyclischen nukleosiden und verwendungen davon
|
CA2887884A1
(en)
|
2012-10-12 |
2014-04-17 |
Isis Pharmaceuticals, Inc. |
Selective antisense compounds and uses thereof
|
ES2762326T5
(es)
|
2012-10-15 |
2023-04-27 |
Ionis Pharmaceuticals Inc |
Métodos para modular la expresión de C9ORF72
|
WO2014062736A1
(en)
|
2012-10-15 |
2014-04-24 |
Isis Pharmaceuticals, Inc. |
Methods for monitoring c9orf72 expression
|
RU2020127664A
(ru)
|
2012-10-15 |
2020-09-17 |
Ионис Фармасьютикалз, Инк. |
Композиции для модуляции экспрессии гена c9orf72
|
US9029335B2
(en)
|
2012-10-16 |
2015-05-12 |
Isis Pharmaceuticals, Inc. |
Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
|
EP2920308B1
(de)
|
2012-10-31 |
2018-12-12 |
Ionis Pharmaceuticals, Inc. |
Krebsbehandlung
|
JP2016509572A
(ja)
|
2012-11-05 |
2016-03-31 |
プロナイ セラピューティクス インコーポレイテッド |
Bcl2発現の調節による癌の処置のためにバイオマーカーを使用する方法
|
US10201556B2
(en)
|
2012-11-06 |
2019-02-12 |
Interna Technologies B.V. |
Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated B-raf pathway
|
KR20150083920A
(ko)
|
2012-11-15 |
2015-07-20 |
로슈 이노베이션 센터 코펜하겐 에이/에스 |
항 apob 안티센스 접합체 화합물
|
BR112015012051A2
(pt)
|
2012-11-26 |
2017-12-12 |
Roche Innovation Ct Copenhagen As |
composições e métodos para modulação de expressão de fgfr3
|
US9695475B2
(en)
|
2012-12-11 |
2017-07-04 |
Ionis Pharmaceuticals, Inc. |
Competitive modulation of microRNAs
|
SG11201504554UA
(en)
|
2012-12-21 |
2015-07-30 |
Alios Biopharma Inc |
Substituted nucleosides, nucleotides and analogs thereof
|
WO2014108759A1
(en)
|
2013-01-14 |
2014-07-17 |
Pierfrancesco Tassone |
INHIBITORS OF miRNAs 221 AND 222 FOR ANTI-TUMOR ACTIVITY IN MULTIPLE MYELOMA
|
US9856474B2
(en)
|
2013-01-16 |
2018-01-02 |
Iowa State University Research Foundation, Inc. |
Deep intronic target for splicing correction on spinal muscular atrophy gene
|
KR20150110562A
(ko)
|
2013-01-30 |
2015-10-02 |
에프. 호프만-라 로슈 아게 |
Lna 올리고뉴클레오타이드 탄수화물 컨쥬게이트
|
WO2014118272A1
(en)
|
2013-01-30 |
2014-08-07 |
Santaris Pharma A/S |
Antimir-122 oligonucleotide carbohydrate conjugates
|
US9701708B2
(en)
|
2013-01-31 |
2017-07-11 |
Ionis Pharmaceuticals, Inc. |
Method of preparing oligomeric compounds using modified coupling protocols
|
CN108743943A
(zh)
|
2013-02-14 |
2018-11-06 |
Ionis制药公司 |
对脂蛋白脂肪酶缺乏群体中的载脂蛋白c-iii(apociii)表达的调节
|
AU2014200958B2
(en)
|
2013-02-25 |
2016-01-14 |
Seegene, Inc. |
Detection of nucleotide variation on target nucleic acid sequence
|
EP2961853B1
(de)
|
2013-02-28 |
2018-09-19 |
The Board of Regents of The University of Texas System |
Verfahren zur klassifizierung einer krebserkrankung als anfälligkeit für tmepai-gerichtete therapien und zur heilung solcher krebserkrankungen
|
US10086093B2
(en)
|
2013-02-28 |
2018-10-02 |
The General Hospital Corporation |
miRNA profiling compositions and methods of use
|
AU2014222150A1
(en)
|
2013-03-01 |
2015-09-10 |
National University Corporation Tokyo Medical And Dental University |
Chimeric single-stranded antisense polynucleotides and double-stranded antisense agent
|
WO2014142575A1
(en)
|
2013-03-13 |
2014-09-18 |
Seegene, Inc. |
Quantification of target nucleic acid using melting peak analysis
|
JP2016515216A
(ja)
|
2013-03-14 |
2016-05-26 |
シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド |
メッセンジャーrnaのキャップ効率の定量的評価
|
JP2016514970A
(ja)
|
2013-03-14 |
2016-05-26 |
シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド |
メッセンジャーrnaのキャップ効率の定量的評価
|
US9273349B2
(en)
|
2013-03-14 |
2016-03-01 |
Affymetrix, Inc. |
Detection of nucleic acids
|
EP2971142B1
(de)
|
2013-03-14 |
2020-06-24 |
Ionis Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur modulation der tau-genexpression
|
US9983206B2
(en)
|
2013-03-15 |
2018-05-29 |
The Board Of Trustees Of The University Of Illinois |
Methods and compositions for enhancing immunoassays
|
US10590412B2
(en)
|
2013-04-19 |
2020-03-17 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulation nucleic acids through nonsense mediated decay
|
CN105358158A
(zh)
|
2013-04-29 |
2016-02-24 |
纪念斯隆-凯特琳癌症中心 |
用于改变第二信使信号传导的组合物和方法
|
RU2686080C2
(ru)
|
2013-05-01 |
2019-04-24 |
Ионис Фармасьютикалз, Инк. |
Композиции и способы
|
JP6472087B2
(ja)
|
2013-05-30 |
2019-02-27 |
国立大学法人 東京医科歯科大学 |
治療用オリゴヌクレオチドを送達するための二本鎖剤
|
ES2862125T3
(es)
|
2013-06-13 |
2021-10-07 |
Antisense Therapeutics Ltd |
Terapia combinada para acromegalia
|
AU2014282666A1
(en)
|
2013-06-16 |
2016-01-07 |
National University Corporation Tokyo Medical And Dental University |
Double-stranded antisense nucleic acid with exon-skipping effect
|
WO2014205449A2
(en)
|
2013-06-21 |
2014-12-24 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating apolipoprotein c-iii expression for improving a diabetic profile
|
DK3013959T3
(da)
|
2013-06-27 |
2020-02-17 |
Roche Innovation Ct Copenhagen As |
Antisense-oligomerer og konjugater målrettet pcsk9
|
EP3730614A3
(de)
|
2013-07-02 |
2020-12-30 |
Ionis Pharmaceuticals, Inc. |
Modulatoren des wachstumshormonrezeptors
|
JP6617702B2
(ja)
|
2013-07-15 |
2019-12-11 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Fty720のアザサイクリック拘束アナログ
|
KR101863943B1
(ko)
|
2013-07-15 |
2018-06-01 |
주식회사 씨젠 |
Pto 절단 및 연장-의존적 고정화 올리고뉴클레오타이드 혼성화를 이용한 타겟 핵산 서열의 검출
|
TWI657819B
(zh)
|
2013-07-19 |
2019-05-01 |
美商Ionis製藥公司 |
用於調節τ蛋白表現之組合物
|
EP3027617A4
(de)
|
2013-07-31 |
2017-04-12 |
Ionis Pharmaceuticals, Inc. |
Verfahren und verbindungen für erkrankungen im zusammenhang mit repeat-expansion
|
PL3041854T3
(pl)
|
2013-08-08 |
2020-06-29 |
The Scripps Research Institute |
Sposób miejscowo specyficznego oznakowania enzymatycznego kwasów nukleinowych in vitro przez inkorporację niewystępujących naturalnie nukleotydów
|
TW201536329A
(zh)
|
2013-08-09 |
2015-10-01 |
Isis Pharmaceuticals Inc |
用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
|
AU2014312196C1
(en)
|
2013-08-28 |
2019-12-19 |
Ionis Pharmaceuticals, Inc. |
Modulation of prekallikrein (PKK) expression
|
PL3043827T3
(pl)
|
2013-09-13 |
2020-03-31 |
Ionis Pharmaceuticals, Inc. |
Modulatory czynnika b dopełniacza
|
EP3052626A1
(de)
|
2013-10-02 |
2016-08-10 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur hemmung der lect2-genexpression
|
UA124961C2
(uk)
|
2013-10-04 |
2021-12-22 |
Елнілем Фармасьютикалз, Інк. |
ДВОНИТКОВА РИБОНУКЛЕЇНОВА КИСЛОТА (dsRNA) ДЛЯ ІНГІБУВАННЯ ЕКСПРЕСІЇ ALAS1
|
MY192689A
(en)
|
2013-10-11 |
2022-09-01 |
Ionis Pharmaceuticals Inc |
Compositions for modulating c9orf72 expression
|
JP6640079B2
(ja)
|
2013-10-16 |
2020-02-05 |
ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア |
小容積の粒子を調製するためのデバイス及び方法
|
CN105705657B
(zh)
|
2013-10-18 |
2020-07-28 |
Seegene株式会社 |
基于利用杂交-捕捉和模板化寡核苷酸的探测和标记寡核苷酸切割及延伸分析的在固相中的靶核酸序列检测
|
WO2015061246A1
(en)
|
2013-10-21 |
2015-04-30 |
Isis Pharmaceuticals, Inc. |
Method for solution phase detritylation of oligomeric compounds
|
US10301622B2
(en)
|
2013-11-04 |
2019-05-28 |
Northwestern University |
Quantification and spatio-temporal tracking of a target using a spherical nucleic acid (SNA)
|
EP3375877A1
(de)
|
2013-11-18 |
2018-09-19 |
Crispr Therapeutics AG |
Crispr-cas-systemmaterialien und verfahren
|
WO2015075166A1
(en)
|
2013-11-22 |
2015-05-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treatment of a bacterial infection
|
CA2932122C
(en)
|
2013-12-03 |
2022-04-19 |
Northwestern University |
Liposomal particles, methods of making same and uses thereof
|
CA2844640A1
(en)
|
2013-12-06 |
2015-06-06 |
The University Of British Columbia |
Method for treatment of castration-resistant prostate cancer
|
US10385388B2
(en)
|
2013-12-06 |
2019-08-20 |
Swift Biosciences, Inc. |
Cleavable competitor polynucleotides
|
WO2015089277A1
(en)
|
2013-12-12 |
2015-06-18 |
The Regents Of The University Of California |
Methods and compositions for modifying a single stranded target nucleic acid
|
SG11201604692UA
(en)
|
2013-12-12 |
2016-07-28 |
Alnylam Pharmaceuticals Inc |
Complement component irna compositions and methods of use thereof
|
WO2015100394A1
(en)
|
2013-12-24 |
2015-07-02 |
Isis Pharmaceuticals, Inc. |
Modulation of angiopoietin-like 3 expression
|
WO2015118407A2
(en)
|
2014-01-29 |
2015-08-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Oligonucleotides and methods for inhibiting or reducing bacterial biofilms
|
CA2937539A1
(en)
|
2014-02-04 |
2015-08-13 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
CN106103718B
(zh)
|
2014-02-11 |
2021-04-02 |
阿尔尼拉姆医药品有限公司 |
己酮糖激酶(KHK)iRNA组合物及其使用方法
|
EP2907874A1
(de)
|
2014-02-14 |
2015-08-19 |
Université de Lausanne |
MiR-21-3p-Inhibitoren bei Hauterkrankungen
|
WO2015142910A1
(en)
|
2014-03-17 |
2015-09-24 |
Isis Pharmaceuticals, Inc. |
Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom
|
EP3119888B1
(de)
|
2014-03-19 |
2021-07-28 |
Ionis Pharmaceuticals, Inc. |
Zusammensetzungen zur modulierung der ataxin-2-expression
|
HUE050704T2
(hu)
|
2014-04-01 |
2020-12-28 |
Biogen Ma Inc |
Összetételek a SOD-1 expressziójának modulálására
|
EP3129493B1
(de)
|
2014-04-09 |
2021-07-07 |
The Scripps Research Institute |
Import von unnatürlichen oder modifizierten nukleosid-triphosphaten in zellen mittels nukleinsäure-triphosphattransportern
|
WO2015164693A1
(en)
|
2014-04-24 |
2015-10-29 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising alpha-beta-constrained nucleic acid
|
EP3137476B1
(de)
|
2014-04-28 |
2019-10-09 |
Ionis Pharmaceuticals, Inc. |
Verbindungsmodifizierte oligomerverbindungen
|
EP3862362A3
(de)
|
2014-05-01 |
2021-10-27 |
Ionis Pharmaceuticals, Inc. |
Konjugate con antisens-oligonukleotides und deren verwendung zur modulation der pkk-expression
|
KR102356388B1
(ko)
|
2014-05-01 |
2022-01-26 |
아이오니스 파마수티컬즈, 인코포레이티드 |
안지오포이에틴-유사 3 발현을 조절하기 위한 조성물 및 방법
|
KR102149571B1
(ko)
|
2014-05-01 |
2020-08-31 |
아이오니스 파마수티컬즈, 인코포레이티드 |
성장 호르몬 수용체 발현을 조절하기 위한 조성물 및 방법
|
RS59182B1
(sr)
|
2014-05-01 |
2019-10-31 |
Ionis Pharmaceuticals Inc |
Kompozicije i postupci za modulaciju ekspresije faktora b komplementa
|
US10098959B2
(en)
|
2014-05-01 |
2018-10-16 |
Ionis Pharmaceuticals, Inc. |
Method for synthesis of reactive conjugate clusters
|
TW201607559A
(zh)
|
2014-05-12 |
2016-03-01 |
阿尼拉製藥公司 |
治療serpinc1相關疾患之方法和組成物
|
GB201408623D0
(en)
|
2014-05-15 |
2014-07-02 |
Santaris Pharma As |
Oligomers and oligomer conjugates
|
MX2016015126A
(es)
|
2014-05-22 |
2017-02-23 |
Alnylam Pharmaceuticals Inc |
Composiciones de angiotensinogeno (agt) arni y metodos de uso de las mismas.
|
EP3508198A1
(de)
|
2014-06-04 |
2019-07-10 |
Exicure, Inc. |
Multivalente ausgabe von immunmodulatoren durch liposomale sphärische nukleinsäuren für prophylaktische oder therapeutische anwendungen
|
WO2015190922A1
(en)
|
2014-06-10 |
2015-12-17 |
Erasmus University Medical Center Rotterdam |
Antisense oligonucleotides useful in treatment of pompe disease
|
GB201410693D0
(en)
|
2014-06-16 |
2014-07-30 |
Univ Southampton |
Splicing modulation
|
TW201620526A
(zh)
|
2014-06-17 |
2016-06-16 |
愛羅海德研究公司 |
用於抑制α-1抗胰蛋白酶基因表現之組合物及方法
|
JP6562517B2
(ja)
*
|
2014-07-31 |
2019-08-21 |
国立大学法人大阪大学 |
架橋型ヌクレオシドおよびヌクレオチド
|
JP6797108B2
(ja)
|
2014-08-19 |
2020-12-09 |
ノースウェスタン ユニバーシティ |
タンパク質/オリゴヌクレオチドコアシェルナノ粒子治療薬
|
IL234246A0
(en)
|
2014-08-21 |
2014-11-30 |
Omrix Biopharmaceuticals Ltd |
Stabilized thrombin
|
WO2016033424A1
(en)
|
2014-08-29 |
2016-03-03 |
Genzyme Corporation |
Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
|
EP3189141B1
(de)
|
2014-09-02 |
2020-06-24 |
Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft |
Gegen die a20 3'-utr region gerichtete antisense-oligonukleotide
|
WO2016040589A1
(en)
|
2014-09-12 |
2016-03-17 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting complement component c5 and methods of use thereof
|
WO2016040748A1
(en)
|
2014-09-12 |
2016-03-17 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for detection of smn protein in a subject and treatment of a subject
|
AU2015318782A1
(en)
|
2014-09-18 |
2017-04-06 |
The University Of British Columbia |
Allele-specific therapy for Huntington Disease haplotypes
|
AU2015323973A1
(en)
|
2014-09-29 |
2017-04-20 |
The Jackson Laboratory |
High efficiency, high throughput generation of genetically modified mammals by electroporation
|
CA2963288A1
(en)
|
2014-10-03 |
2016-04-07 |
Cold Spring Harbor Laboratory |
Targeted augmentation of nuclear gene output
|
WO2016061131A1
(en)
|
2014-10-14 |
2016-04-21 |
The J. David Gladstone Institutes |
Compositions and methods for reactivating latent immunodeficiency virus
|
EP3207138B1
(de)
|
2014-10-17 |
2020-07-15 |
Alnylam Pharmaceuticals, Inc. |
Gegen aminolävulinsäuresynthase-1 (alas1) gerichtete polynukleotidmittel und verwendungen davon
|
EP3212794B1
(de)
|
2014-10-30 |
2021-04-07 |
Genzyme Corporation |
Polynukleotidwirkstoffe mit abzielung auf serpinc1 (at3) und verfahren zur verwendung davon
|
AU2015344741A1
(en)
|
2014-11-10 |
2017-05-25 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Combination long acting compositions and methods for hepatitis C
|
WO2016075583A1
(en)
|
2014-11-10 |
2016-05-19 |
Glaxosmithkline Intelle Ctual Property (No.2) Limited |
Long acting pharmaceutical compositions for hepatitis c
|
JOP20200092A1
(ar)
|
2014-11-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
|
WO2016081444A1
(en)
|
2014-11-17 |
2016-05-26 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
|
AU2015349680A1
(en)
|
2014-11-21 |
2017-06-08 |
Northwestern University |
The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
|
WO2016086104A1
(en)
|
2014-11-25 |
2016-06-02 |
Ionis Pharmaceuticals, Inc. |
Modulation of ube3a-ats expression
|
EP3234141A4
(de)
|
2014-12-18 |
2018-06-20 |
Alnylam Pharmaceuticals, Inc. |
Reversir-tm-verbindungen
|
CA2970966A1
(en)
|
2014-12-22 |
2016-06-30 |
Anapa Biotech A/S |
Dual quenching assay for multiplex detection of target nucleic acids
|
US9688707B2
(en)
|
2014-12-30 |
2017-06-27 |
Ionis Pharmaceuticals, Inc. |
Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
|
JP2018512597A
(ja)
|
2015-02-04 |
2018-05-17 |
ジェネンテック, インコーポレイテッド |
突然変異体スムースンド及びその使用方法
|
CA2976445A1
(en)
|
2015-02-13 |
2016-08-18 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
EP3256591A4
(de)
|
2015-02-13 |
2018-08-08 |
Translate Bio Ma, Inc. |
Hybride oligonukleotide und verwendungen davon
|
US10426789B2
(en)
|
2015-02-26 |
2019-10-01 |
Ionis Pharmaceuticals, Inc. |
Allele specific modulators of P23H rhodopsin
|
US20180044673A1
(en)
|
2015-03-03 |
2018-02-15 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating mecp2 expression
|
EP3265098A4
(de)
|
2015-03-03 |
2019-02-13 |
Ionis Pharmaceuticals, Inc. |
Zusammensetzungen zur modulierung der mecp2 -expression
|
BR112017015864A2
(pt)
|
2015-04-03 |
2018-07-31 |
Ionis Pharmaceuticals, Inc. |
compostos e métodos para modular a expressão de tmprss6
|
WO2016164746A1
(en)
|
2015-04-08 |
2016-10-13 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
ES2846902T3
(es)
|
2015-04-08 |
2021-07-30 |
Univ Chicago |
Composiciones y procedimientos para corregir la distrofia muscular de cinturas tipo 2C mediante omisión de exones
|
TWI723986B
(zh)
|
2015-04-13 |
2021-04-11 |
美商阿尼拉製藥公司 |
類血管生成素3(ANGPTL3)iRNA組成物及其用途方法
|
KR102258516B1
(ko)
|
2015-04-16 |
2021-05-31 |
아이오니스 파마수티컬즈, 인코포레이티드 |
C9orf72 발현을 조절하기 위한 조성물
|
WO2016196655A1
(en)
|
2015-06-03 |
2016-12-08 |
The Regents Of The University Of California |
Cas9 variants and methods of use thereof
|
EP3307316A1
(de)
|
2015-06-12 |
2018-04-18 |
Alnylam Pharmaceuticals, Inc. |
Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon
|
WO2016205323A1
(en)
|
2015-06-18 |
2016-12-22 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
|
WO2016209862A1
(en)
|
2015-06-23 |
2016-12-29 |
Alnylam Pharmaceuticals, Inc. |
Glucokinase (gck) irna compositions and methods of use thereof
|
US10494632B2
(en)
|
2015-07-10 |
2019-12-03 |
Alnylam Pharmaceuticals, Inc. |
Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
|
AU2016295168B2
(en)
|
2015-07-17 |
2021-08-19 |
Alnylam Pharmaceuticals, Inc. |
Multi-targeted single entity conjugates
|
WO2017023861A1
(en)
|
2015-08-03 |
2017-02-09 |
The Regents Of The University Of California |
Compositions and methods for modulating abhd2 activity
|
WO2017032726A1
(en)
|
2015-08-24 |
2017-03-02 |
Roche Innovation Center Copenhagen A/S |
Lna-g process
|
AU2016315584B2
(en)
|
2015-09-02 |
2022-07-14 |
Alnylam Pharmaceuticals, Inc. |
Programmed cell death 1 ligand 1 (PD-L1) iRNA compositions and methods of use thereof
|
WO2017048620A1
(en)
|
2015-09-14 |
2017-03-23 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof
|
DK3350347T3
(da)
|
2015-09-14 |
2021-04-19 |
Pentabase Aps |
Fremgangsmåder og materialer til detektion af mutationer
|
WO2017048843A1
(en)
|
2015-09-14 |
2017-03-23 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the alas1 gene
|
TW201718618A
(zh)
|
2015-09-18 |
2017-06-01 |
田邊三菱製藥股份有限公司 |
架橋型核酸GuNA,其製造方法,及中間體化合物
|
WO2017053990A1
(en)
|
2015-09-24 |
2017-03-30 |
The Regents Of The University Of California |
Synthetic sphingolipid-like molecules, drugs, methods of their synthesis and methods of treatment
|
JP2018532402A
(ja)
|
2015-09-24 |
2018-11-08 |
クリスパー セラピューティクス アーゲー |
Rnaプログラム可能エンドヌクレアーゼの新規のファミリーならびにゲノム編集および他の適用におけるそれらの使用
|
US10533175B2
(en)
|
2015-09-25 |
2020-01-14 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating Ataxin 3 expression
|
IL295971A
(en)
|
2015-10-08 |
2022-10-01 |
Ionis Pharmaceuticals Inc |
Compounds and methods for modulating the expression of angiotensinogen
|
US10196639B2
(en)
|
2015-10-09 |
2019-02-05 |
University Of Southampton |
Modulation of gene expression and screening for deregulated protein expression
|
WO2017066782A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Hydrophobic mrna cap analogs
|
WO2017066789A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Mrna cap analogs with modified sugar
|
WO2017066791A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Sugar substituted mrna cap analogs
|
ES2914225T3
(es)
|
2015-10-16 |
2022-06-08 |
Modernatx Inc |
Análogos de cap de ARNm con enlace de fosfato modificado
|
EP3362460A1
(de)
|
2015-10-16 |
2018-08-22 |
Modernatx, Inc. |
Mrna-kappenanaloga und verfahren zum mrna-kappen
|
EP3183347A4
(de)
|
2015-10-17 |
2018-04-18 |
Lifesplice Pharma LLC |
Spleissmodulierende oligonukleotide und verfahren zur verwendung davon
|
WO2017068087A1
(en)
|
2015-10-22 |
2017-04-27 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide detection method
|
EP3368692B1
(de)
|
2015-10-29 |
2021-07-21 |
Temple University Of The Commonwealth System Of Higher Education |
Modifizierung von 3'-endstücken von nukleinsäuren durch dna-polymerase-theta
|
US11260073B2
(en)
|
2015-11-02 |
2022-03-01 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating C90RF72
|
EP3371201A4
(de)
|
2015-11-06 |
2019-09-18 |
Ionis Pharmaceuticals, Inc. |
Konjugierte antisense-verbindungen zur verwendung in der therapie
|
CA2999341A1
(en)
|
2015-11-06 |
2017-05-11 |
Ionis Pharmaceuticals, Inc. |
Modulating apolipoprotein (a) expression
|
MX2018004978A
(es)
|
2015-11-12 |
2018-07-06 |
Hoffmann La Roche |
Oligonucleotidos para inducir la expresion paterna de la ligasa de la proteina ubiquitina e3a (ube3a).
|
CA3005968A1
(en)
|
2015-11-23 |
2017-06-01 |
The Regents Of The University Of California |
Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9
|
CA3007152A1
(en)
|
2015-12-07 |
2017-06-15 |
Erasmus University Medical Center Rotterdam |
Enzymatic replacement therapy and antisense therapy for pompe disease
|
RU2754188C2
(ru)
|
2015-12-07 |
2021-08-30 |
Джензим Корпорейшн |
Способы и композиции для лечения ассоциированного с serpinc1 расстройства
|
EP3656872A1
(de)
|
2015-12-09 |
2020-05-27 |
Novartis AG |
Markierungsfreie analyse der rna-kappungseffizienz mit rnase h, sonden und flüssigchromatografie/massenspektrometrie
|
JP2018536689A
(ja)
|
2015-12-10 |
2018-12-13 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
ステロール調節エレメント結合タンパク質(SREBP)シャペロン(SCAP)iRNA組成物およびその使用方法
|
EP3390636B1
(de)
|
2015-12-14 |
2021-05-19 |
Cold Spring Harbor Laboratory |
Antisense-oligomere zur behandlung von dravet-syndrom
|
US11096956B2
(en)
|
2015-12-14 |
2021-08-24 |
Stoke Therapeutics, Inc. |
Antisense oligomers and uses thereof
|
JOP20200228A1
(ar)
|
2015-12-21 |
2017-06-16 |
Novartis Ag |
تركيبات وطرق لخفض تعبير البروتين tau
|
CA3006599A1
(en)
|
2016-01-05 |
2017-07-13 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing lrrk2 expression
|
EP3400097B1
(de)
|
2016-01-06 |
2021-01-27 |
The University Of British Columbia |
Verzweigte mischer sowie verfahren zu deren verwendung und herstellung
|
WO2017124086A1
(en)
|
2016-01-15 |
2017-07-20 |
The Jackson Laboratory |
Genetically modified non-human mammals by multi-cycle electroporation of cas9 protein
|
CA3019952A1
(en)
|
2016-02-04 |
2017-08-10 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
EP3418289A4
(de)
|
2016-02-17 |
2019-10-30 |
Tokyo Institute of Technology |
Künstliches nukleosid und künstliches nukleotid und künstliches oligonukleotid
|
US11008608B2
(en)
|
2016-02-26 |
2021-05-18 |
The Board Of Trustees Of The Leland Stanford Junior University |
Multiplexed single molecule RNA visualization with a two-probe proximity ligation system
|
CA3013797A1
(en)
|
2016-03-09 |
2017-09-14 |
Ionis Pharmaceuticals, Inc. |
Methods and compositions for inhibiting pmp22 expression
|
JP6748219B2
(ja)
|
2016-03-14 |
2020-08-26 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
Pd−l1発現低減用のオリゴヌクレオチド
|
CA3013799A1
(en)
|
2016-03-16 |
2017-09-21 |
Ionis Pharmaceuticals, Inc. |
Methods of modulating keap1
|
ES2933435T3
(es)
|
2016-04-13 |
2023-02-08 |
Ionis Pharmaceuticals Inc |
Métodos para reducir la expresión de C9ORF72
|
US11248019B2
(en)
|
2016-04-14 |
2022-02-15 |
Hoffmann-La Roche Inc. |
Trityl-mono-GalNAc compounds and their use
|
MA45295A
(fr)
|
2016-04-19 |
2019-02-27 |
Alnylam Pharmaceuticals Inc |
Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser
|
SG11201809002RA
(en)
|
2016-04-29 |
2018-11-29 |
Univ Nanyang Tech |
G-quadruplex-containing antisense oligonucleotides
|
CA3021994A1
(en)
|
2016-05-06 |
2017-11-09 |
Brett P. Monia |
Glp-1 receptor ligand moiety conjugated oligonucleotides and uses thereof
|
KR102639586B1
(ko)
|
2016-06-06 |
2024-02-23 |
애로우헤드 파마슈티컬스 인코포레이티드 |
5'-시클로-포스포네이트 변형된 뉴클레오티드
|
JP2019518028A
(ja)
|
2016-06-10 |
2019-06-27 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
補体成分C5iRNA組成物及び発作性夜間血色素尿症(PNH)を処置するためのその使用方法
|
ES2929381T3
(es)
|
2016-06-15 |
2022-11-28 |
Streck Inc |
Ensayos y métodos para determinar la resistencia microbiana
|
US10337051B2
(en)
|
2016-06-16 |
2019-07-02 |
The Regents Of The University Of California |
Methods and compositions for detecting a target RNA
|
MA45496A
(fr)
|
2016-06-17 |
2019-04-24 |
Hoffmann La Roche |
Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b
|
DK3475295T3
(da)
|
2016-06-24 |
2022-10-24 |
Scripps Research Inst |
Hidtil ukendt nukleosidtriphosphat-transportør og anvendelser deraf
|
CN109415732B
(zh)
|
2016-07-01 |
2024-01-02 |
豪夫迈·罗氏有限公司 |
用于调节htra1表达的反义寡核苷酸
|
IL264216B2
(en)
|
2016-07-15 |
2024-04-01 |
Ionis Pharmaceuticals Inc |
Compounds and Methods for Modulating SMN2
|
US20220354888A1
(en)
|
2016-08-03 |
2022-11-10 |
Aalborg Universitet |
ANTISENSE OLIGONUCLEOTIDES (ASOs) DESIGNED TO INHIBIT IMMUNE CHECKPOINT PROTEINS
|
NL2017294B1
(en)
|
2016-08-05 |
2018-02-14 |
Univ Erasmus Med Ct Rotterdam |
Natural cryptic exon removal by pairs of antisense oligonucleotides.
|
NL2017295B1
(en)
|
2016-08-05 |
2018-02-14 |
Univ Erasmus Med Ct Rotterdam |
Antisense oligomeric compound for Pompe disease
|
US11364304B2
(en)
|
2016-08-25 |
2022-06-21 |
Northwestern University |
Crosslinked micellar spherical nucleic acids
|
SG10201607303YA
(en)
|
2016-09-01 |
2018-04-27 |
Agency Science Tech & Res |
Antisense oligonucleotides to induce exon skipping
|
CN110072530A
(zh)
*
|
2016-09-02 |
2019-07-30 |
迪克纳制药公司 |
4′-磷酸酯类似物和包含其的寡核苷酸
|
JOP20190065A1
(ar)
|
2016-09-29 |
2019-03-28 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن tau
|
KR20190065341A
(ko)
|
2016-10-06 |
2019-06-11 |
아이오니스 파마수티컬즈, 인코포레이티드 |
올리고머 화합물들의 접합 방법
|
WO2018075827A1
(en)
|
2016-10-19 |
2018-04-26 |
Arcturus Therapeutics, Inc. |
Trinucleotide mrna cap analogs
|
SG10201609048RA
(en)
|
2016-10-28 |
2018-05-30 |
Agency Science Tech & Res |
Antisense oligonucleotides
|
JOP20190104A1
(ar)
|
2016-11-10 |
2019-05-07 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن atxn3
|
WO2018087200A1
(en)
|
2016-11-11 |
2018-05-17 |
Roche Innovation Center Copenhagen A/S |
Therapeutic oligonucleotides capture and detection
|
TWI788312B
(zh)
|
2016-11-23 |
2023-01-01 |
美商阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法
|
WO2018102745A1
(en)
|
2016-12-02 |
2018-06-07 |
Cold Spring Harbor Laboratory |
Modulation of lnc05 expression
|
US11371090B2
(en)
|
2016-12-12 |
2022-06-28 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for molecular barcoding of DNA molecules prior to mutation enrichment and/or mutation detection
|
SG10201913552UA
(en)
|
2016-12-16 |
2020-03-30 |
Alnylam Pharmaceuticals Inc |
Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions
|
AU2017386771A1
(en)
|
2016-12-28 |
2019-06-20 |
Daiichi Sankyo Company, Limited |
Therapeutic drug for Alport's syndrome
|
AU2018208505B2
(en)
|
2017-01-10 |
2024-03-07 |
Arrowhead Pharmaceuticals, Inc. |
Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use
|
US20200216845A1
(en)
|
2017-01-13 |
2020-07-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating rela expression
|
US20190338286A1
(en)
|
2017-01-13 |
2019-11-07 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating rel expression
|
EP3568481A1
(de)
|
2017-01-13 |
2019-11-20 |
Roche Innovation Center Copenhagen A/S |
Antisense-oligonukleotide zur modulierung der relb-expression
|
EP3568479A1
(de)
|
2017-01-13 |
2019-11-20 |
Roche Innovation Center Copenhagen A/S |
Antisense-oligonukleotide zur modulierung der nfkb1-expression
|
EP3568480A1
(de)
|
2017-01-13 |
2019-11-20 |
Roche Innovation Center Copenhagen A/S |
Antisense-oligonukleotide zur modulierung der nfkb2-expression
|
JP7188087B2
(ja)
|
2017-02-06 |
2022-12-13 |
日産化学株式会社 |
一本鎖オリゴヌクレオチド
|
WO2018165564A1
(en)
|
2017-03-09 |
2018-09-13 |
Ionis Pharmaceuticals, Inc. |
Morpholino modified oligomeric compounds
|
WO2018164275A1
(ja)
|
2017-03-10 |
2018-09-13 |
国立研究開発法人国立成育医療研究センター |
アンチセンスオリゴヌクレオチドおよび糖原病Ia型予防または治療用組成物
|
JOP20190215A1
(ar)
|
2017-03-24 |
2019-09-19 |
Ionis Pharmaceuticals Inc |
مُعدّلات التعبير الوراثي عن pcsk9
|
JP7190794B2
(ja)
|
2017-03-29 |
2022-12-16 |
塩野義製薬株式会社 |
核酸医薬及び多分岐脂質の複合体
|
CN110913898B
(zh)
|
2017-04-18 |
2024-04-05 |
阿尔尼拉姆医药品有限公司 |
具有乙肝病毒(hbv)感染的受试者的治疗方法
|
CA3062595A1
(en)
|
2017-05-10 |
2018-11-15 |
The Regents Of The University Of California |
Directed editing of cellular rna via nuclear delivery of crispr/cas9
|
US20190055564A1
(en)
|
2017-06-01 |
2019-02-21 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides for modulating htra1 expression
|
EP3599844A4
(de)
|
2017-06-07 |
2021-01-13 |
University of Massachusetts |
Anti-adam33-oligonukleotide und zugehörige verfahren
|
AU2018300069A1
(en)
|
2017-07-11 |
2020-02-27 |
Synthorx, Inc. |
Incorporation of unnatural nucleotides and methods thereof
|
MX2020000387A
(es)
|
2017-07-13 |
2020-08-17 |
Univ Northwestern |
Método general y directo para preparar nanopartículas de estructura organometálica funcionalizadas con oligonucleotidos.
|
US11174511B2
(en)
|
2017-07-24 |
2021-11-16 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for selecting and amplifying DNA targets in a single reaction mixture
|
US11555188B2
(en)
|
2017-07-26 |
2023-01-17 |
Nissan Chemical Corporation |
Single-stranded oligonucleotide
|
CA3071013A1
(en)
|
2017-08-03 |
2019-02-07 |
Synthorx, Inc. |
Cytokine conjugates for the treatment of proliferative and infectious diseases
|
WO2019030313A2
(en)
|
2017-08-11 |
2019-02-14 |
Roche Innovation Center Copenhagen A/S |
OLIGONUCLEOTIDES FOR MODULATION OF UBE3C EXPRESSION
|
CA3071033A1
(en)
|
2017-08-18 |
2019-02-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of the notch signaling pathway for treatment of respiratory disorders
|
DK3669193T3
(da)
*
|
2017-08-18 |
2022-07-11 |
European Molecular Biology Laboratory |
Forbedret rna-interaktom-registrering (eric)
|
WO2019038228A1
(en)
|
2017-08-22 |
2019-02-28 |
Roche Innovation Center Copenhagen A/S |
OLIGONUCLEOTIDES FOR MODULATION OF TOM1 EXPRESSION
|
WO2019040923A1
(en)
|
2017-08-25 |
2019-02-28 |
Stoke Therapeutics, Inc. |
ANTISENSE OLIGOMERS FOR THE TREATMENT OF DISEASE CONDITIONS AND OTHER DISEASES
|
KR102380264B1
(ko)
|
2017-08-31 |
2022-03-29 |
주식회사 씨젠 |
다이머-형성 프라이머 쌍을 이용한 구성요소의 성능 평가
|
US11401546B2
(en)
|
2017-09-29 |
2022-08-02 |
Seegene, Inc. |
Detection of target nucleic acid sequences by PTO cleavage and extension-dependent extension assay
|
JP2021502059A
(ja)
|
2017-10-13 |
2021-01-28 |
ロシュ イノベーション センター コペンハーゲン エーエス |
部分的に立体定義されたオリゴヌクレオチドのサブライブラリーを使用することによる、アンチセンスオリゴヌクレオチドの、改良された立体定義されたホスホロチオエートオリゴヌクレオチド変異体を同定するための方法
|
TWI762732B
(zh)
|
2017-10-16 |
2022-05-01 |
瑞士商赫孚孟拉羅股份公司 |
用於降低PAPD5及PAPD7 mRNA以治療B型肝炎感染之核酸分子
|
EP3697904A1
(de)
|
2017-10-17 |
2020-08-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Kombinationsbehandlung für zystische fibrose
|
EP3704252A1
(de)
|
2017-11-01 |
2020-09-09 |
Alnylam Pharmaceuticals, Inc. |
Gegen komplementkomponente c3 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon
|
AU2018358016A1
(en)
|
2017-11-03 |
2020-05-07 |
Interna Technologies B.V. |
MiRNA molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation
|
TWI809004B
(zh)
|
2017-11-09 |
2023-07-21 |
美商Ionis製藥公司 |
用於降低snca表現之化合物及方法
|
WO2019099610A1
(en)
|
2017-11-16 |
2019-05-23 |
Alnylam Pharmaceuticals, Inc. |
Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
|
WO2019100039A1
(en)
|
2017-11-20 |
2019-05-23 |
Alnylam Pharmaceuticals, Inc. |
Serum amyloid p component (apcs) irna compositions and methods of use thereof
|
WO2019111791A1
(ja)
*
|
2017-12-07 |
2019-06-13 |
第一三共株式会社 |
ジストロフィン遺伝子のイントロンリテンションを解消するアンチセンスオリゴヌクレオチド
|
EP3724333A2
(de)
|
2017-12-11 |
2020-10-21 |
Roche Innovation Center Copenhagen A/S |
Oligonukleotide zur modulierung der fndc3b-expression
|
WO2019115417A2
(en)
|
2017-12-12 |
2019-06-20 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating rb1 expression
|
EP4257691A3
(de)
|
2017-12-14 |
2024-01-10 |
Ionis Pharmaceuticals, Inc. |
Konjugierte antisense-verbindungen und deren verwendung
|
AU2018386301A1
(en)
|
2017-12-14 |
2020-06-18 |
Bayer Healthcare Llc |
Novel RNA-programmable endonuclease systems and their use in genome editing and other applications
|
EP3724355A1
(de)
|
2017-12-15 |
2020-10-21 |
Novartis AG |
Polya-schwanzlängenanalyse der rna mittels massenspektrometrie
|
KR20200110655A
(ko)
|
2017-12-18 |
2020-09-24 |
알닐람 파마슈티칼스 인코포레이티드 |
고이동성 그룹 박스-1 (hmgb1) irna 조성물 및 이의 사용 방법
|
CA3085211A1
(en)
|
2017-12-21 |
2019-06-27 |
F. Hoffmann-La Roche Ag |
Companion diagnostic for htra1 rna antagonists
|
KR20200104345A
(ko)
|
2017-12-22 |
2020-09-03 |
로슈 이노베이션 센터 코펜하겐 에이/에스 |
포스포로디티오에이트 뉴클레오시드간 연결을 포함하는 올리고뉴클레오티드
|
EP4092117A1
(de)
|
2017-12-22 |
2022-11-23 |
Roche Innovation Center Copenhagen A/S |
Gapmer-oligonukleotide mit einer phosphordithioat-internukleosidverknüpfung
|
CN111448316A
(zh)
|
2017-12-22 |
2020-07-24 |
罗氏创新中心哥本哈根有限公司 |
新的硫代亚磷酰胺
|
CN111699258A
(zh)
|
2018-01-10 |
2020-09-22 |
哥本哈根罗氏创新中心 |
用于调控pias4表达的寡核苷酸
|
JP2021510295A
(ja)
|
2018-01-12 |
2021-04-22 |
ロシュ イノベーション センター コペンハーゲン エーエス |
Gsk3b発現を調節するためのオリゴヌクレオチド
|
US11447775B2
(en)
|
2018-01-12 |
2022-09-20 |
Bristol-Myers Squibb Company |
Antisense oligonucleotides targeting alpha-synuclein and uses thereof
|
MX2020006973A
(es)
|
2018-01-12 |
2020-09-09 |
Roche Innovation Ct Copenhagen As |
Oligonucleotidos antisentido para alfa-sinucleina y usos de los mismos.
|
CA3087966A1
(en)
|
2018-01-12 |
2019-07-18 |
Bristol-Myers Squibb Company |
Antisense oligonucleotides targeting alpha-synuclein and uses thereof
|
MX2020007369A
(es)
|
2018-01-15 |
2020-10-28 |
Ionis Pharmaceuticals Inc |
Moduladores de la expresion de dnm2.
|
WO2019141656A1
(en)
|
2018-01-17 |
2019-07-25 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating erc1 expression
|
EP3740573A1
(de)
|
2018-01-18 |
2020-11-25 |
Roche Innovation Center Copenhagen A/S |
Gegen srebp1 gerichtete antisense-oligonukleotide
|
WO2019145386A1
(en)
|
2018-01-26 |
2019-08-01 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating csnk1d expression
|
CA3088071A1
(en)
|
2018-02-09 |
2019-08-15 |
Genentech, Inc. |
Oligonucleotides for modulating tmem106b expression
|
EP3752164A1
(de)
|
2018-02-12 |
2020-12-23 |
InteRNA Technologies B.V. |
Antikrebs-mikrorna und lipidformulierungen davon
|
US11332733B2
(en)
|
2018-02-12 |
2022-05-17 |
lonis Pharmaceuticals, Inc. |
Modified compounds and uses thereof
|
SG11202007652UA
(en)
|
2018-02-21 |
2020-09-29 |
Bristol Myers Squibb Co |
Camk2d antisense oligonucleotides and uses thereof
|
MX2020008772A
(es)
|
2018-02-26 |
2020-10-01 |
Synthorx Inc |
Conjugados de il-15, y sus usos.
|
US11958878B2
(en)
|
2018-03-09 |
2024-04-16 |
Daiichi Sankyo Company, Limited |
Therapeutic agent for glycogen storage disease type IA
|
CA3092497A1
(en)
|
2018-03-19 |
2019-09-26 |
Crispr Therapeutics Ag |
Novel rna-programmable endonuclease systems and uses thereof
|
CA3094303A1
(en)
|
2018-03-20 |
2019-09-26 |
Tokyo Institute Of Technology |
Antisense oligonucleotide reduced in toxicity
|
EP3775208A1
(de)
|
2018-04-05 |
2021-02-17 |
F. Hoffmann-La Roche AG |
Verwendung von fubp1-inhibitoren zur behandlung von hepatitis-b-virus-infektionen
|
EP3553182A1
(de)
|
2018-04-11 |
2019-10-16 |
Université de Bourgogne |
Verfahren zum nachweis von somatischen genetischen anomalien, kombination von fangsonden und nachweiskit
|
MX2020011695A
(es)
|
2018-05-04 |
2021-02-26 |
Stoke Therapeutics Inc |
Métodos y composiciones para el tratamiento de la enfermedad por almacenamiento de éster de colesterilo.
|
WO2019215066A1
(en)
|
2018-05-07 |
2019-11-14 |
Roche Innovation Center Copenhagen A/S |
Quality control of lna oligonucleotide therapeutics using massively parallel sequencing
|
JP7353301B2
(ja)
|
2018-05-07 |
2023-09-29 |
アルニラム ファーマスーティカルズ インコーポレイテッド |
肝臓外送達
|
EP3790971A1
(de)
|
2018-05-08 |
2021-03-17 |
Roche Innovation Center Copenhagen A/S |
Oligonukleotide zur modulierung der myh7-expression
|
JOP20200280A1
(ar)
|
2018-05-09 |
2020-11-05 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير الوراثي عن fxi
|
CN118685406A
(zh)
|
2018-05-14 |
2024-09-24 |
阿尔尼拉姆医药品有限公司 |
血管紧张素原(AGT)iRNA组合物及其使用方法
|
WO2019219723A1
(en)
|
2018-05-18 |
2019-11-21 |
F. Hoffmann-La Roche Ag |
Pharmaceutical compositions for treatment of microrna related diseases
|
WO2019224172A1
(en)
|
2018-05-25 |
2019-11-28 |
Roche Innovation Center Copenhagen A/S |
Novel process for making allofuranose from glucofuranose
|
WO2019233921A1
(en)
|
2018-06-05 |
2019-12-12 |
F. Hoffmann-La Roche Ag |
Oligonucleotides for modulating atxn2 expression
|
CN112218950A
(zh)
|
2018-06-13 |
2021-01-12 |
第一三共株式会社 |
心肌损伤治疗药
|
JP2021528068A
(ja)
|
2018-06-21 |
2021-10-21 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
全lnaオリゴヌクレオチドのハイブリダイズ
|
WO2020007772A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting gbp-1
|
WO2020007702A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting bcl2l11
|
WO2020007700A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting spi1
|
PE20210346A1
(es)
|
2018-07-03 |
2021-02-25 |
Hoffmann La Roche |
Oligonucleotidos para modular la expresion de tau
|
WO2020007889A1
(en)
|
2018-07-05 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting stat1
|
WO2020007826A1
(en)
|
2018-07-05 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting mbtps1
|
WO2020011653A1
(en)
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting kynu
|
WO2020011743A1
(en)
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting mafb
|
WO2020011869A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting tlr2
|
WO2020011744A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting cers5
|
WO2020011745A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting cers6
|
PE20211306A1
(es)
|
2018-07-13 |
2021-07-20 |
Hoffmann La Roche |
Oligonucleotidos para modular la expresion de rtel1
|
AU2019310097A1
(en)
|
2018-07-25 |
2021-02-04 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing ATXN2 expression
|
WO2020022499A1
(ja)
|
2018-07-27 |
2020-01-30 |
国立大学法人大阪大学 |
老化の抑制、加齢性の疾患もしくは症状の予防、改善、もしくは治療、または寿命の延長のための組成物
|
BR112020025272A2
(pt)
|
2018-07-31 |
2021-03-09 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotídeos, oligonucleotídeo gapmer, sal farmaceuticamente aceitável, conjugado, composição farmacêutica, usos de um oligonucleotídeo, método para o tratamento ou profilaxia de uma doença, processo para a fabricação de um oligonucleotídeo e invenção
|
MX2021001019A
(es)
|
2018-07-31 |
2021-04-19 |
Roche Innovation Ct Copenhagen As |
Oligonucleotidos que comprenden enlace internucleosidico de fosforotritioato.
|
JP6544783B1
(ja)
|
2018-07-31 |
2019-07-17 |
学校法人 岩手医科大学 |
がんの診断のためのプローブ/プライマーライブラリー
|
EP4442836A2
(de)
|
2018-08-01 |
2024-10-09 |
Mammoth Biosciences, Inc. |
Programmierbare nukleasezusammensetzungen und verfahren zur verwendung davon
|
MX2021001056A
(es)
|
2018-08-13 |
2021-04-12 |
Alnylam Pharmaceuticals Inc |
Composiciones de agente de acido ribonucleico bicatenario (arnbc) de virus de la hepatitis b (vhb) y metodos de uso de las mismas.
|
TW202020157A
(zh)
|
2018-08-16 |
2020-06-01 |
美商艾爾妮蘭製藥公司 |
用於抑制lect2基因表現之組合物及方法
|
EP3840733A4
(de)
|
2018-08-20 |
2022-07-20 |
Rogcon, Inc. |
Gegen scn2a gerichtete antisense-oligonukleotide zur behandlung von scn1a-enzephalopathien
|
WO2020038976A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting usp8
|
WO2020038968A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Microrna-134 biomarker
|
WO2020038971A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting vcan
|
WO2020038973A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting sptlc1
|
EP3844274A1
(de)
|
2018-08-28 |
2021-07-07 |
Roche Innovation Center Copenhagen A/S |
Neoantigen-engineering unter verwendung von spleissmodulierenden verbindungen
|
EP3620519A1
(de)
|
2018-09-04 |
2020-03-11 |
F. Hoffmann-La Roche AG |
Verwendung von isolierten extrazellulären vesikeln aus milch zur oralen verabreichung von oligonukleotiden
|
WO2020068398A2
(en)
|
2018-09-07 |
2020-04-02 |
The General Hospital Corporation |
Compositions and methods for immune checkpoint inhibition
|
EP3620520A1
(de)
|
2018-09-10 |
2020-03-11 |
Universidad del Pais Vasco |
Neuartiges target zur behandlung einer stoffwechselerkrankung in einem individuum
|
WO2020056341A2
(en)
|
2018-09-14 |
2020-03-19 |
Northwestern University |
Programming protein polymerization with dna
|
US20210332367A1
(en)
|
2018-09-18 |
2021-10-28 |
Alnylam Pharmaceuticals, Inc. |
KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
TW202423454A
(zh)
|
2018-09-19 |
2024-06-16 |
美商Ionis製藥公司 |
Pnpla3表現之調節劑
|
TW202028465A
(zh)
|
2018-09-28 |
2020-08-01 |
美商阿尼拉製藥公司 |
甲狀腺素運載蛋白(TTR)iRNA組成物及其治療或預防TTR相關眼部疾病之使用方法
|
US10913951B2
(en)
|
2018-10-31 |
2021-02-09 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
|
CN112969709A
(zh)
|
2018-11-01 |
2021-06-15 |
豪夫迈·罗氏有限公司 |
靶向tia1的反义寡核苷酸
|
JP7356448B2
(ja)
|
2018-11-12 |
2023-10-04 |
田辺三菱製薬株式会社 |
架橋型人工核酸alna
|
CN113646430A
(zh)
|
2018-11-15 |
2021-11-12 |
Ionis制药公司 |
Irf5表达的调节剂
|
BR112021009419A2
(pt)
|
2018-11-16 |
2021-08-17 |
F. Hoffmann-La Roche Ag |
fase sólida, método de preparação de uma fase sólida, uso, kit para determinar um analito em uma amostra, complexo e métodos para formar um complexo e para determinar um analito em uma amostra
|
TWI841633B
(zh)
|
2018-11-21 |
2024-05-11 |
美商Ionis製藥公司 |
用於減少朊病毒表現之化合物及方法
|
WO2020104492A1
(en)
|
2018-11-22 |
2020-05-28 |
Roche Innovation Center Copenhagen A/S |
Pyridinium salts as activators in the synthesis of stereodefined oligonucleotides
|
WO2020109344A1
(en)
|
2018-11-29 |
2020-06-04 |
F. Hoffmann-La Roche Ag |
Occular administration device for antisense oligonucleotides
|
WO2020109343A1
(en)
|
2018-11-29 |
2020-06-04 |
F. Hoffmann-La Roche Ag |
Combination therapy for treatment of macular degeneration
|
US20210332495A1
(en)
|
2018-12-06 |
2021-10-28 |
Northwestern University |
Protein Crystal Engineering Through DNA Hybridization Interactions
|
WO2020132521A1
(en)
|
2018-12-20 |
2020-06-25 |
Praxis Precision Medicines, Inc. |
Compositions and methods for the treatment of kcnt1 related disorders
|
CN113330118A
(zh)
|
2018-12-21 |
2021-08-31 |
勃林格殷格翰国际有限公司 |
靶向card9的反义寡核苷酸
|
EP3931313A2
(de)
|
2019-01-04 |
2022-01-05 |
Mammoth Biosciences, Inc. |
Verbesserungen an programmierbarer nuklease und zusammensetzungen und verfahren zur nukleinsäureamplifikation und -detektion
|
MX2021008628A
(es)
|
2019-01-16 |
2021-11-17 |
Genzyme Corp |
Composiciones de arni para serpinc1 y metodos de uso de las mismas.
|
DE102019000490A1
(de)
|
2019-01-23 |
2020-07-23 |
HAEMES Verwaltungsgesellschaft mbH |
Verwendung von Oligonukleotiden für die Behandlung von Tumoren
|
EP3914232A1
(de)
|
2019-01-25 |
2021-12-01 |
F. Hoffmann-La Roche AG |
Lipidvesikel zur oralen wirkstoffverabreichung
|
BR112021014415A2
(pt)
|
2019-02-06 |
2021-09-21 |
Synthorx, Inc. |
Conjugados de il-2 e métodos de uso dos mesmos
|
MX2021009949A
(es)
|
2019-02-20 |
2021-09-21 |
Roche Innovation Ct Copenhagen As |
Fosforamiditas novedosas.
|
KR20210128410A
(ko)
|
2019-02-20 |
2021-10-26 |
로슈 이노베이션 센터 코펜하겐 에이/에스 |
포스포노아세트산 갭머 올리고뉴클레오티드
|
JP7503072B2
(ja)
|
2019-02-26 |
2024-06-19 |
ロシュ イノベーション センター コペンハーゲン エーエス |
オリゴヌクレオチドの製剤化方法
|
MX2021010152A
(es)
|
2019-02-27 |
2021-09-14 |
Ionis Pharmaceuticals Inc |
Moduladores de la expresion de malat1.
|
WO2020178258A1
(en)
|
2019-03-05 |
2020-09-10 |
F. Hoffmann-La Roche Ag |
Intracellular targeting of molecules
|
CA3130789A1
(en)
|
2019-03-07 |
2020-09-10 |
The Regents Of The University Of California |
Crispr-cas effector polypeptides and methods of use thereof
|
WO2020186059A2
(en)
|
2019-03-12 |
2020-09-17 |
Crispr Therapeutics Ag |
Novel high fidelity rna-programmable endonuclease systems and uses thereof
|
EP3981431A4
(de)
|
2019-03-14 |
2023-06-28 |
Rena Therapeutics Inc. |
Nukleinsäurekomplex zur modulation der ihh-expression
|
US20240108747A1
(en)
|
2019-03-21 |
2024-04-04 |
Lonza Sales Ag |
Extracellular vesicle conjugates and uses thereof
|
WO2020191177A1
(en)
|
2019-03-21 |
2020-09-24 |
Sudhir Agrawal |
Antisense oligonucleotides for allele specificity
|
MX2021011916A
(es)
|
2019-03-29 |
2021-10-26 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para modular ube3a-ats.
|
EP3950006A4
(de)
|
2019-03-29 |
2024-06-12 |
Mitsubishi Tanabe Pharma Corporation |
Verbindung, verfahren und pharmazeutische zusammensetzung zur einstellung der dux4-expression
|
CN113906139A
(zh)
|
2019-04-03 |
2022-01-07 |
百时美施贵宝公司 |
Angptl2反义寡核苷酸及其用途
|
JP7499267B2
(ja)
|
2019-04-04 |
2024-06-13 |
エフ. ホフマン-ラ ロシュ アーゲー |
Atxn2発現を調節するためのオリゴヌクレオチド
|
US11286485B2
(en)
|
2019-04-04 |
2022-03-29 |
Hoffmann-La Roche Inc. |
Oligonucleotides for modulating ATXN2 expression
|
US20220194976A1
(en)
|
2019-04-16 |
2022-06-23 |
Roche Innovation Center Copenhagen A/S |
Novel Process for Preparing Nucleotide P(V) Monomers
|
US20220194972A1
(en)
|
2019-04-30 |
2022-06-23 |
Roche Innovation Center Copenhagen A/S |
Novel Process for Preparing Rhenium Chelated MAG3 Oligonucleotides
|
CN114072501A
(zh)
|
2019-05-06 |
2022-02-18 |
马萨诸塞大学 |
抗c9orf72寡核苷酸及相关方法
|
WO2020236600A1
(en)
|
2019-05-17 |
2020-11-26 |
Alnylam Pharmaceuticals, Inc. |
Oral delivery of oligonucleotides
|
TW202111123A
(zh)
|
2019-05-28 |
2021-03-16 |
美商Ionis製藥公司 |
用於減少fus 表現之化合物及方法
|
WO2020243644A1
(en)
|
2019-05-31 |
2020-12-03 |
Streck, Inc. |
Detection of antibiotic resistance genes
|
AU2020287787A1
(en)
|
2019-06-05 |
2022-01-20 |
Daiichi Sankyo Company, Limited |
Stable target-editing guide RNA having chemically modified nucleic acid introduced thereinto
|
JP7155302B2
(ja)
|
2019-06-06 |
2022-10-18 |
エフ.ホフマン-ラ ロシュ アーゲー |
Atxn3を標的とするアンチセンスオリゴヌクレオチド
|
BR112021024624A2
(pt)
|
2019-06-07 |
2022-01-18 |
Hoffmann La Roche |
Métodos para selecionar e fornecer um par de ligação de oligonucleotídeos de fita simples, para formar um duplex antiparalelo e para realizar um ensaio, par de ss-oligonucleotídeos complementares separados, duplex antiparalelo, uso de um par de ss-oligonucleotídeos separados, kit para realizar um ensaio e composição líquida
|
WO2020252262A1
(en)
|
2019-06-14 |
2020-12-17 |
The Scripps Research Institute |
Reagents and methods for replication, transcription, and translation in semi-synthetic organisms
|
EP3988558A4
(de)
|
2019-06-19 |
2022-09-28 |
Yamasa Corporation |
Vernetzter nukleosidzwischenkristall und verfahren zu seiner herstellung sowie verfahren zur herstellung von vernetztem nukleosidamidit
|
EP3995153A4
(de)
|
2019-06-26 |
2023-11-22 |
KNC Laboratories Co., Ltd. |
Nukleinsäurearzneimittel zur unterdrückung der produktion von myostatin-mrna
|
CN110204583B
(zh)
*
|
2019-07-01 |
2021-03-23 |
中国人民解放军军事科学院军事医学研究院 |
修饰核苷、核苷酸和修饰核酸聚合物及其制备方法和应用
|
WO2021005223A1
(en)
|
2019-07-10 |
2021-01-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of epilepsy
|
US20220364086A1
(en)
|
2019-07-12 |
2022-11-17 |
Daiichi Sankyo Company, Limited |
ANTISENSE OLIGONUCLEOTIDE CAPABLE OF ALTERING SPLICING OF DUX4 pre-mRNA
|
WO2021021673A1
(en)
|
2019-07-26 |
2021-02-04 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating gfap
|
EP4005602A4
(de)
|
2019-07-30 |
2024-06-12 |
Shionogi & Co., Ltd |
Gegen murf1 gerichteter nukleinsäurewirkstoff
|
EP4007811A2
(de)
|
2019-08-01 |
2022-06-08 |
Alnylam Pharmaceuticals, Inc. |
Carboxypeptidase-b2(cpb2)-irna-zusammensetzungen und verfahren zur verwendung davon
|
WO2021022109A1
(en)
|
2019-08-01 |
2021-02-04 |
Alnylam Pharmaceuticals, Inc. |
SERPIN FAMILY F MEMBER 2 (SERPINF2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
WO2021030522A1
(en)
|
2019-08-13 |
2021-02-18 |
Alnylam Pharmaceuticals, Inc. |
SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
JP2022544289A
(ja)
|
2019-08-14 |
2022-10-17 |
コディアック バイオサイエンシーズ, インコーポレイテッド |
Stat6を標的とする細胞外小胞-aso構築物
|
CA3147365A1
(en)
|
2019-08-14 |
2021-02-18 |
Joanne LIM |
Extracellular vesicle-nlrp3 antagonist
|
EP4013878A1
(de)
|
2019-08-14 |
2022-06-22 |
Codiak BioSciences, Inc. |
Extrazelluläre vesikel mit aso-konstrukten gegen cebp/beta
|
WO2021030769A1
(en)
|
2019-08-14 |
2021-02-18 |
Codiak Biosciences, Inc. |
Extracellular vesicles with nras antisense oligonucleotides
|
CA3145924A1
(en)
|
2019-08-14 |
2021-02-18 |
Yi Zhang |
Extracellular vesicle linked to molecules and uses thereof
|
CN114641570A
(zh)
|
2019-08-14 |
2022-06-17 |
科迪亚克生物科学公司 |
具有靶向kras的反义寡核苷酸的细胞外囊泡
|
CN114555621A
(zh)
|
2019-08-15 |
2022-05-27 |
Ionis制药公司 |
键修饰的寡聚化合物及其用途
|
US20220290152A1
(en)
|
2019-09-03 |
2022-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
BR112022004461A2
(pt)
|
2019-09-10 |
2022-07-19 |
Daiichi Sankyo Co Ltd |
Conjugado de galnac-oligonucleotídeo para entrega ao fígado e método de fabricação do mesmo
|
WO2021062058A1
(en)
|
2019-09-25 |
2021-04-01 |
Codiak Biosciences, Inc. |
Sting agonist comprising exosomes for treating neuroimmunological disorders
|
IT201900017234A1
(it)
|
2019-09-25 |
2021-03-25 |
Int Centre For Genetic Engineering And Biotechnology |
Anti-miRNA per il trattamento del leiomioma
|
CN110590886B
(zh)
*
|
2019-09-26 |
2021-03-23 |
中国人民解放军军事科学院军事医学研究院 |
修饰核苷、核苷酸和核酸聚合物及其制备方法与应用
|
WO2021067747A1
(en)
|
2019-10-04 |
2021-04-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing ugt1a1 gene expression
|
EP4045062A1
(de)
|
2019-10-14 |
2022-08-24 |
Astrazeneca AB |
Modulatoren der pnpla3-expression
|
WO2021074657A1
(en)
|
2019-10-17 |
2021-04-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combination treatment for cystic fibrosis
|
CN114502565A
(zh)
*
|
2019-10-18 |
2022-05-13 |
第一三共株式会社 |
制造二环亚磷酰胺的方法
|
WO2021076828A1
(en)
|
2019-10-18 |
2021-04-22 |
Alnylam Pharmaceuticals, Inc. |
Solute carrier family member irna compositions and methods of use thereof
|
MX2022004726A
(es)
|
2019-10-22 |
2022-05-13 |
Alnylam Pharmaceuticals Inc |
Composiciones de acido ribonucleico de interferencia (arni) de componente c3 de complemento y metodos de uso de las mismas.
|
EP4052730A4
(de)
*
|
2019-10-28 |
2023-06-14 |
National University Corporation Tokai National Higher Education and Research System |
Nukleosidderivat und verwendung davon
|
TW202132567A
(zh)
|
2019-11-01 |
2021-09-01 |
美商阿尼拉製藥公司 |
亨汀頓蛋白(HTT)iRNA劑組成物及其使用方法
|
EP4051796A1
(de)
|
2019-11-01 |
2022-09-07 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zum unterdrücken der dnajb1-prkaca-fusionsgenexpression
|
KR20220110749A
(ko)
|
2019-11-06 |
2022-08-09 |
알닐람 파마슈티칼스 인코포레이티드 |
간외 전달
|
WO2021092145A1
(en)
|
2019-11-06 |
2021-05-14 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr) irna composition and methods of use thereof for treating or preventing ttr-associated ocular diseases
|
CA3161703A1
(en)
|
2019-11-13 |
2021-05-20 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating an angiotensinogen- (agt-) associated disorder
|
WO2021099394A1
(en)
|
2019-11-19 |
2021-05-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antisense oligonucleotides and their use for the treatment of cancer
|
EP4061945A1
(de)
|
2019-11-22 |
2022-09-28 |
Alnylam Pharmaceuticals, Inc. |
Ataxin3 (atxn3)-rnai-wirkstoffzusammensetzungen und verfahren zu deren verwendung
|
US20220411841A1
(en)
|
2019-11-27 |
2022-12-29 |
Crispr Therapeutics Ag |
Methods of synthesizing rna molecules
|
CN115176001A
(zh)
|
2019-12-11 |
2022-10-11 |
因特利亚治疗公司 |
用于基因编辑的修饰的引导rna
|
KR20220115995A
(ko)
|
2019-12-13 |
2022-08-19 |
알닐람 파마슈티칼스 인코포레이티드 |
인간 염색체 9 개방 판독 프레임 72 (C9orf72) iRNA 제제 조성물 및 이의 사용 방법
|
WO2021126734A1
(en)
|
2019-12-16 |
2021-06-24 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
JP7500727B2
(ja)
|
2019-12-18 |
2024-06-17 |
エフ. ホフマン-ラ ロシュ アーゲー |
連続的な標識スキームを使用した合成による配列決定方法
|
EP4077667A1
(de)
|
2019-12-19 |
2022-10-26 |
F. Hoffmann-La Roche AG |
Verwendung von sept9-inhibitoren zum behandeln von hepatitis-b-virus-infektionen
|
JP2023506540A
(ja)
|
2019-12-19 |
2023-02-16 |
エフ. ホフマン-ラ ロシュ エージー. |
B型肝炎ウイルス感染を処置するためのscamp3阻害剤の使用
|
CN114867856A
(zh)
|
2019-12-19 |
2022-08-05 |
豪夫迈·罗氏有限公司 |
Saraf抑制剂用于治疗乙型肝炎病毒感染的用途
|
WO2021122910A1
(en)
|
2019-12-19 |
2021-06-24 |
F. Hoffmann-La Roche Ag |
Use of sbds inhibitors for treating hepatitis b virus infection
|
EP4077670A1
(de)
|
2019-12-19 |
2022-10-26 |
F. Hoffmann-La Roche AG |
Verwendung von cops3-inhibitoren zum behandeln von hepatitis-b-virus-infektionen
|
EP4077672A1
(de)
|
2019-12-20 |
2022-10-26 |
F. Hoffmann-La Roche AG |
Verbesserte oligonukleotide zur hemmung der scn9a-expression
|
AU2020415322A1
(en)
|
2019-12-24 |
2022-06-16 |
F. Hoffmann-La Roche Ag |
Pharmaceutical combination of antiviral agents targeting HBV and/or an immune modulator for treatment of HBV
|
EP4081639A1
(de)
|
2019-12-24 |
2022-11-02 |
F. Hoffmann-La Roche AG |
Pharmazeutische kombination eines therapeutischen oligonucleotids gegen hbv und eines tlr7-agonisten zur behandlung von hbv
|
CA3169474A1
(en)
|
2020-01-31 |
2021-08-05 |
Sanwa Kagaku Kenkyusho Co., Ltd. |
Antisense oligonucleotide of atn1
|
WO2021158810A1
(en)
|
2020-02-05 |
2021-08-12 |
Bristol-Myers Squibb Company |
Oligonucleotides for splice modulation of camk2d
|
JP2023514190A
(ja)
|
2020-02-10 |
2023-04-05 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Vegf-a発現をサイレンシングするための組成物および方法
|
TWI775313B
(zh)
|
2020-02-18 |
2022-08-21 |
美商基利科學股份有限公司 |
抗病毒化合物
|
JP7429799B2
(ja)
|
2020-02-18 |
2024-02-08 |
ギリアード サイエンシーズ, インコーポレイテッド |
抗ウイルス化合物
|
IL295496A
(en)
|
2020-02-18 |
2022-10-01 |
Alnylam Pharmaceuticals Inc |
Apolipoprotein c3 (apoc3) irna preparations and methods of using them
|
TW202322824A
(zh)
|
2020-02-18 |
2023-06-16 |
美商基利科學股份有限公司 |
抗病毒化合物
|
JP2023516142A
(ja)
|
2020-02-28 |
2023-04-18 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Cd73エクソン7スプライシングを調節するためのオリゴヌクレオチド
|
MX2022010602A
(es)
|
2020-02-28 |
2022-09-09 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para modular smn2.
|
JPWO2021177418A1
(de)
|
2020-03-04 |
2021-09-10 |
|
|
WO2021178607A1
(en)
|
2020-03-05 |
2021-09-10 |
Alnylam Pharmaceuticals, Inc. |
Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
|
CN115461460A
(zh)
|
2020-03-06 |
2022-12-09 |
阿尔尼拉姆医药品有限公司 |
用于抑制转甲状腺素蛋白(ttr)的表达的组合物和方法
|
CN115485383A
(zh)
|
2020-03-06 |
2022-12-16 |
阿尔尼拉姆医药品有限公司 |
己酮糖激酶(KHK)iRNA组合物及其使用方法
|
WO2021182517A1
(ja)
|
2020-03-11 |
2021-09-16 |
隆光 矢野 |
-1フレームシフトを誘導するための1本鎖核酸分子及び組成物
|
WO2021184020A1
(en)
|
2020-03-13 |
2021-09-16 |
Codiak Biosciences, Inc. |
Methods of treating neuroinflammation
|
WO2021184021A1
(en)
|
2020-03-13 |
2021-09-16 |
Codiak Biosciences, Inc. |
Extracellular vesicle-aso constructs targeting pmp22
|
EP4121534A1
(de)
|
2020-03-18 |
2023-01-25 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur behandlung von patienten mit einer heterozygoten alaninglyoxylat-aminotransferase-genvariante (agxt)
|
EP4127168A1
(de)
|
2020-03-26 |
2023-02-08 |
Alnylam Pharmaceuticals, Inc. |
Coronavirus-irna-zusammensetzungen und verfahren zur verwendung davon
|
EP4127171A2
(de)
|
2020-03-30 |
2023-02-08 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur ausschaltung der dnajc15-genexpression
|
CN115843299A
(zh)
|
2020-03-31 |
2023-03-24 |
詹森生物制药有限公司 |
寡核苷酸的合成和相关化合物
|
WO2021207167A1
(en)
|
2020-04-06 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing myoc expression
|
CN116134135A
(zh)
|
2020-04-07 |
2023-05-16 |
阿尔尼拉姆医药品有限公司 |
用于沉默scn9a表达的组合物和方法
|
WO2021206917A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
EP4133077A1
(de)
|
2020-04-07 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Irna-zusammensetzungen mit transmembran-serinprotease 2 (tmprss2) und verfahren zur verwendung davon
|
MX2022013525A
(es)
|
2020-04-27 |
2023-01-24 |
Alnylam Pharmaceuticals Inc |
Composiciones de agentes de ácido ribonucleico de interferencia (arni) de apolipoproteína e (apoe) y métodos de uso de las mismas.
|
EP4142738A1
(de)
|
2020-04-30 |
2023-03-08 |
Alnylam Pharmaceuticals, Inc. |
Komplementfaktor-b (cfb)-irna-zusammensetzungen und verfahren zur verwendung davon
|
JP2023527684A
(ja)
|
2020-05-11 |
2023-06-30 |
ジェネンテック, インコーポレイテッド |
神経疾患を治療するための補体成分c1s阻害剤、並びにそれを使用する関連組成物、システム及び方法
|
EP4150092A1
(de)
|
2020-05-11 |
2023-03-22 |
Stoke Therapeutics, Inc. |
Opa1-antisense-oligomere zur behandlung von erkrankungen und leiden
|
EP4150084A1
(de)
|
2020-05-11 |
2023-03-22 |
Genentech, Inc. |
Komplementkomponente-4-inhibitoren zur behandlung neurologischer erkrankungen und zugehörige zusammensetzungen, systeme und verfahren zur verwendung davon
|
WO2021231210A1
(en)
|
2020-05-11 |
2021-11-18 |
Genentech, Inc. |
Complement component c1r inhibitors for treating a neurological disease, and related compositions, systems and methods of using same
|
EP4151237A4
(de)
|
2020-05-12 |
2024-08-14 |
Mitsubishi Tanabe Pharma Corp |
Verbindung, verfahren und pharmazeutische zusammensetzung zur regulierung der expression von ataxin 3
|
JP2023526267A
(ja)
|
2020-05-13 |
2023-06-21 |
エフ. ホフマン-ラ ロシュ アーゲー |
プログラニュリン標的オリゴヌクレオチドアゴニスト
|
EP4150078A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten editierung von argininosuccinat-lyase (asl)
|
WO2021231691A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi)
|
CA3162416C
(en)
|
2020-05-15 |
2023-07-04 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
|
EP4150086A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von leucinreicher repeat-kinase 2 (lrrk2)
|
WO2021231692A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of otoferlin (otof)
|
EP4150077A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von transmembrankanalähnlichem protein 1 (tmc1)
|
EP4150087A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung des gap-junction-proteins beta 2 (gjb2)
|
EP4150076A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von methyl-cpg-bindendem protein 2 (mecp2)
|
EP4153746A1
(de)
|
2020-05-21 |
2023-03-29 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur hemmung der marc1-genexpression
|
US20230193269A1
(en)
|
2020-05-22 |
2023-06-22 |
Boehringer Ingelheim International Gmbh |
Oligonucleotides for splice modulation of card9
|
AR122534A1
(es)
|
2020-06-03 |
2022-09-21 |
Triplet Therapeutics Inc |
Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3
|
EP4162047A1
(de)
|
2020-06-09 |
2023-04-12 |
Roche Innovation Center Copenhagen A/S |
Guanosinanaloga zur verwendung in therapeutischen polynukleotiden
|
EP4162050A1
(de)
|
2020-06-09 |
2023-04-12 |
Alnylam Pharmaceuticals, Inc. |
Rnai-zusammensetzungen und verfahren zur verwendung davon zur verabreichung durch inhalation
|
AU2021292296A1
(en)
|
2020-06-18 |
2023-01-19 |
Alnylam Pharmaceuticals, Inc. |
Xanthine dehydrogenase (XDH) iRNA compositions and methods of use thereof
|
AR122731A1
(es)
|
2020-06-26 |
2022-10-05 |
Hoffmann La Roche |
Oligonucleótidos mejorados para modular la expresión de fubp1
|
CN111732623B
(zh)
*
|
2020-06-30 |
2022-01-18 |
中国科学院化学研究所 |
一种三异丙基硅乙炔修饰的脱氧胞苷亚磷酰胺单体及其制备方法与应用
|
KR20230034333A
(ko)
|
2020-07-02 |
2023-03-09 |
라이프 테크놀로지스 코포레이션 |
트리뉴클레오티드 캡 유사체, 제조 및 이의 용도
|
US20230235315A1
(en)
|
2020-07-10 |
2023-07-27 |
Horizon Discovery Limited |
Method for producing genetically modified cells
|
KR20230050336A
(ko)
|
2020-07-10 |
2023-04-14 |
인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인 썸) |
뇌전증을 치료하기 위한 방법과 조성물
|
US20230257745A1
(en)
|
2020-07-10 |
2023-08-17 |
Alnylam Pharmaceuticals, Inc. |
Circular siRNAs
|
CN116209761A
(zh)
|
2020-07-23 |
2023-06-02 |
豪夫迈·罗氏有限公司 |
靶向rna结合蛋白位点的寡核苷酸
|
WO2022018155A1
(en)
|
2020-07-23 |
2022-01-27 |
F. Hoffmann-La Roche Ag |
Lna oligonucleotides for splice modulation of stmn2
|
WO2022024833A1
(ja)
|
2020-07-28 |
2022-02-03 |
神戸天然物化学株式会社 |
アンギオテンシン変換酵素2遺伝子のエクソンのスキッピングを誘導するアンチセンス核酸
|
WO2022038211A2
(en)
|
2020-08-21 |
2022-02-24 |
F. Hoffmann-La Roche Ag |
Use of a1cf inhibitors for treating hepatitis b virus infection
|
TW202227102A
(zh)
|
2020-09-22 |
2022-07-16 |
瑞典商阿斯特捷利康公司 |
治療脂肪肝病之方法
|
EP4217489A1
(de)
|
2020-09-24 |
2023-08-02 |
Alnylam Pharmaceuticals, Inc. |
Dipeptidylpeptidase 4 (dpp4)-irna-zusammensetzungen und verfahren zur verwendung davon
|
EP4225917A1
(de)
|
2020-10-05 |
2023-08-16 |
Alnylam Pharmaceuticals, Inc. |
G-protein-gekoppelter rezeptor-75 (gpr75)-irna-zusammensetzungen und verfahren zur verwendung davon
|
WO2022076596A1
(en)
|
2020-10-06 |
2022-04-14 |
Codiak Biosciences, Inc. |
Extracellular vesicle-aso constructs targeting stat6
|
EP4232582A1
(de)
|
2020-10-23 |
2023-08-30 |
Alnylam Pharmaceuticals, Inc. |
Mucin-5b (muc5b)-irna-zusammensetzungen und verfahren zur verwendung davon
|
CN116507727A
(zh)
|
2020-11-06 |
2023-07-28 |
住友制药株式会社 |
Rps25基因的表达和/或功能调节剂
|
WO2022103999A1
(en)
|
2020-11-13 |
2022-05-19 |
Alnylam Pharmaceuticals, Inc. |
COAGULATION FACTOR V (F5) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
JP2023550935A
(ja)
|
2020-11-18 |
2023-12-06 |
レンバ・ベーフェー |
Umliloアンチセンス転写阻害剤
|
US11447521B2
(en)
|
2020-11-18 |
2022-09-20 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating angiotensinogen expression
|
EP4247949A1
(de)
|
2020-11-23 |
2023-09-27 |
Alpha Anomeric SAS |
Nukleinsäureduplexe
|
US20230060373A1
(en)
|
2020-12-03 |
2023-03-02 |
Hoffmann-La Roche Inc. |
Antisense Oligonucleotides Targeting ATXN3
|
AR124229A1
(es)
|
2020-12-03 |
2023-03-01 |
Hoffmann La Roche |
Oligonucleótidos antisentido que actúan sobre atxn3
|
WO2022122613A1
(en)
|
2020-12-08 |
2022-06-16 |
F. Hoffmann-La Roche Ag |
Novel synthesis of phosphorodithioate oligonucleotides
|
WO2022125490A1
(en)
|
2020-12-08 |
2022-06-16 |
Alnylam Pharmaceuticals, Inc. |
Coagulation factor x (f10) irna compositions and methods of use thereof
|
MX2023006714A
(es)
|
2020-12-08 |
2023-07-13 |
Univ Fukuoka |
Acido ribonucleico (arn) guia estable de edicion de objetivo al cual se introduce acido nucleico quimicamente modificado.
|
GB2603454A
(en)
|
2020-12-09 |
2022-08-10 |
Ucl Business Ltd |
Novel therapeutics for the treatment of neurodegenerative disorders
|
CN116472276A
(zh)
*
|
2020-12-11 |
2023-07-21 |
雅玛山酱油株式会社 |
胞嘧啶型交联型核苷亚磷酰胺晶体及其制造方法
|
EP4263831A1
(de)
|
2020-12-18 |
2023-10-25 |
F. Hoffmann-La Roche AG |
Antisense oligonukleotide zum targeting von progranulin
|
AR124408A1
(es)
|
2020-12-18 |
2023-03-22 |
Ionis Pharmaceuticals Inc |
Compuestos y métodos para modular el factor xii
|
WO2022136140A1
(en)
|
2020-12-22 |
2022-06-30 |
F. Hoffmann-La Roche Ag |
Oligonucleotides targeting xbp1
|
US20240336914A1
(en)
|
2020-12-31 |
2024-10-10 |
Alnylam Pharmaceuticals, Inc. |
2'-modified nucleoside based oligonucleotide prodrugs
|
JP2024501857A
(ja)
|
2020-12-31 |
2024-01-16 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
環状ジスルフィド修飾リン酸ベースのオリゴヌクレオチドプロドラッグ
|
EP4274896A1
(de)
|
2021-01-05 |
2023-11-15 |
Alnylam Pharmaceuticals, Inc. |
Komplementkomponente 9 (c9)-irna-zusammensetzungen und verfahren zur verwendung davon
|
TW202246500A
(zh)
|
2021-02-02 |
2022-12-01 |
瑞士商赫孚孟拉羅股份公司 |
用於抑制 rtel1 表現之增強型寡核苷酸
|
AU2022220704A1
(en)
|
2021-02-12 |
2022-08-18 |
Alnylam Pharmaceuticals, Inc. |
Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases
|
JP2024506371A
(ja)
|
2021-02-12 |
2024-02-13 |
メランド ファーマシューティカルズ,インコーポレイテッド |
低酸素症及び虚血関連障害を処置する薬剤、組成物及び方法
|
KR20230147125A
(ko)
|
2021-02-17 |
2023-10-20 |
론자 세일즈 아게 |
세포외 소포-nlrp3 길항제
|
CA3207947A1
(en)
|
2021-02-17 |
2022-08-25 |
Aaron Noyes |
Extracellular vesicle linked to a biologically active molecule via an optimized linker and an anchoring moiety
|
CN117222739A
(zh)
|
2021-02-25 |
2023-12-12 |
阿尔尼拉姆医药品有限公司 |
朊病毒蛋白(prnp)irna组合物和其使用方法
|
CA3211059A1
(en)
|
2021-02-26 |
2022-09-01 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk) irna compositions and methods of use thereof
|
EP4299743A1
(de)
|
2021-02-26 |
2024-01-03 |
KNC Laboratories Co., Ltd. |
Nukleinsäurearzneimittel, das eine spleissvariante von myostatin exprimiert
|
IL305442A
(en)
|
2021-03-04 |
2023-10-01 |
Alnylam Pharmaceuticals Inc |
Angiopoietin-like 3 (ANGPTL3) IRNA compositions and methods of using them
|
US20220288181A1
(en)
|
2021-03-12 |
2022-09-15 |
Northwestern University |
Antiviral vaccines using spherical nucleic acids
|
WO2022192519A1
(en)
|
2021-03-12 |
2022-09-15 |
Alnylam Pharmaceuticals, Inc. |
Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
|
AU2022242781A1
(en)
|
2021-03-26 |
2023-10-26 |
Neumirna Therapeutics Aps |
Microrna-27b inhibitors
|
CN117440815A
(zh)
|
2021-03-26 |
2024-01-23 |
神经微核糖核酸治疗有限公司 |
微小rna-134抑制剂
|
BR112023019981A2
(pt)
|
2021-03-29 |
2023-12-12 |
Alnylam Pharmaceuticals Inc |
Composições do agente irna de huntingtina (htt) e métodos de uso das mesmas
|
WO2022241408A1
(en)
|
2021-05-10 |
2022-11-17 |
Entrada Therapeutics, Inc. |
Compositions and methods for modulating tissue distribution of intracellular therapeutics
|
JP2024519601A
(ja)
|
2021-03-31 |
2024-05-20 |
エントラーダ セラピューティクス,インコーポレイティド |
環状細胞透過性ペプチド
|
WO2022212153A1
(en)
|
2021-04-01 |
2022-10-06 |
Alnylam Pharmaceuticals, Inc. |
Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof
|
EP4304566A1
(de)
|
2021-04-01 |
2024-01-17 |
Lonza Sales AG |
Extrazelluläre vesikelzusammensetzungen
|
EP4323362A1
(de)
|
2021-04-16 |
2024-02-21 |
Gilead Sciences, Inc. |
Verfahren zur herstellung von carbanukleosiden mit amiden
|
BR112023022284A2
(pt)
|
2021-04-26 |
2023-12-26 |
Alnylam Pharmaceuticals Inc |
Composições de irna de protease transmembrana, serina 6 (tmprss6) e métodos de uso da mesma
|
WO2022232343A1
(en)
|
2021-04-29 |
2022-11-03 |
Alnylam Pharmaceuticals, Inc. |
Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof
|
JP2024518476A
(ja)
|
2021-05-10 |
2024-05-01 |
エントラーダ セラピューティクス,インコーポレイティド |
mRNAスプライシングを調節するための組成物及び方法
|
EP4337263A1
(de)
|
2021-05-10 |
2024-03-20 |
Entrada Therapeutics, Inc. |
Zusammensetzungen und verfahren zur modulation der interferon-regulatorischen faktor-5 (irf-5)-aktivität
|
JP2024522068A
(ja)
|
2021-05-18 |
2024-06-11 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
ナトリウム-グルコース共輸送体2(sglt2)irna組成物およびその使用方法
|
WO2022246023A1
(en)
|
2021-05-20 |
2022-11-24 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
CN117412773A
(zh)
|
2021-05-31 |
2024-01-16 |
瑞纳治疗公司 |
配体结合核酸复合物
|
WO2022256283A2
(en)
|
2021-06-01 |
2022-12-08 |
Korro Bio, Inc. |
Methods for restoring protein function using adar
|
EP4347823A1
(de)
|
2021-06-02 |
2024-04-10 |
Alnylam Pharmaceuticals, Inc. |
Patin-ähnliche phospholipasedomäne mit 3 (pnpla3)-irna-zusammensetzungen und verfahren zur verwendung davon
|
AU2022283796A1
(en)
|
2021-06-04 |
2023-11-09 |
Alnylam Pharmaceuticals, Inc. |
HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
CN117642505A
(zh)
|
2021-06-04 |
2024-03-01 |
神经微核糖核酸治疗有限公司 |
靶向腺苷激酶的反义寡核苷酸
|
JP2024520636A
(ja)
|
2021-06-04 |
2024-05-24 |
トランスレイト バイオ, インコーポレイテッド |
mRNAキャッピング効率の定量的評価のためのアッセイ
|
WO2022260939A2
(en)
|
2021-06-08 |
2022-12-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating or preventing stargardt's disease and/or retinal binding protein 4 (rbp4)-associated disorders
|
TW202313976A
(zh)
|
2021-06-08 |
2023-04-01 |
瑞士商赫孚孟拉羅股份公司 |
寡核苷酸顆粒蛋白前體促效劑
|
BR112023025724A2
(pt)
|
2021-06-10 |
2024-02-27 |
Intellia Therapeutics Inc |
Rnas-guia modificados que compreendem um ligante interno para edição de gene
|
EP4101928A1
(de)
|
2021-06-11 |
2022-12-14 |
Bayer AG |
Programmierbare typ-v-rna-endonukleasesysteme
|
EP4352214A1
(de)
|
2021-06-11 |
2024-04-17 |
Bayer AG |
Typ-v-rna-programmierbare endonukleasesysteme
|
IL309445A
(en)
|
2021-06-22 |
2024-02-01 |
Acurastem Inc |
PIKFYVE antisense oligonucleotides
|
WO2022271818A1
(en)
|
2021-06-23 |
2022-12-29 |
Entrada Therapeutics, Inc. |
Antisense compounds and methods for targeting cug repeats
|
EP4363574A1
(de)
|
2021-06-29 |
2024-05-08 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen für adar-vermittelte bearbeitung
|
US20230194709A9
(en)
|
2021-06-29 |
2023-06-22 |
Seagate Technology Llc |
Range information detection using coherent pulse sets with selected waveform characteristics
|
KR20240026203A
(ko)
|
2021-06-30 |
2024-02-27 |
알닐람 파마슈티칼스 인코포레이티드 |
안지오텐시노겐(agt)-관련 장애를 치료하는 방법 및 조성물
|
EP4367237A2
(de)
|
2021-07-09 |
2024-05-15 |
Alnylam Pharmaceuticals, Inc. |
Bis-rnai-verbindungen zur zns-verabreichung
|
KR20240025633A
(ko)
|
2021-07-12 |
2024-02-27 |
주식회사 씨젠 |
용기에 수용된 용액의 높이를 결정하는 방법 및 시스템
|
EP4373934A1
(de)
|
2021-07-19 |
2024-05-29 |
Alnylam Pharmaceuticals, Inc. |
Verfahren und zusammensetzungen zur behandlung von patienten mit oder mit einem risiko zur entwicklung einer nichtprimären hyperoxalurieerkrankung oder -störung
|
WO2023003922A1
(en)
|
2021-07-21 |
2023-01-26 |
Alnylam Pharmaceuticals, Inc. |
Metabolic disorder-associated target gene irna compositions and methods of use thereof
|
IL310303A
(en)
|
2021-07-21 |
2024-03-01 |
Acurastem Inc |
UNC13A mol-read oligonucleotides
|
EP4373933A1
(de)
|
2021-07-23 |
2024-05-29 |
Alnylam Pharmaceuticals, Inc. |
Beta-catenin (ctnb1)-irna-zusammensetzungen und verfahren zur verwendung davon
|
JP2024529437A
(ja)
|
2021-07-29 |
2024-08-06 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
3-ヒドロキシ-3-メチルグリタル-COAレダクターゼ(HMGCR)iRNA組成物およびその使用方法
|
MX2024001194A
(es)
|
2021-08-03 |
2024-02-27 |
Alnylam Pharmaceuticals Inc |
Composiciones de acido ribonucleico de interferencia (arni) de transtiretina (ttr) y sus metodos de uso.
|
WO2023014765A1
(en)
|
2021-08-04 |
2023-02-09 |
Alnylam Pharmaceuticals, Inc. |
iRNA COMPOSITIONS AND METHODS FOR SILENCING ANGIOTENSINOGEN (AGT)
|
WO2023019246A1
(en)
|
2021-08-13 |
2023-02-16 |
Alnylam Pharmaceuticals, Inc. |
Factor xii (f12) irna compositions and methods of use thereof
|
CA3229305A1
(en)
|
2021-08-16 |
2023-02-23 |
Vib Vzw |
Oligonucleotides for modulating synaptogyrin-3 expression
|
CA3229568A1
(en)
|
2021-08-17 |
2023-02-23 |
Korea Advanced Institute Of Science And Technology |
Antisense oligonucleotide targeting cav3.1 gene and uses thereof
|
US12116380B2
(en)
|
2021-08-18 |
2024-10-15 |
Gilead Sciences, Inc. |
Phospholipid compounds and methods of making and using the same
|
AU2022329462A1
(en)
|
2021-08-19 |
2024-03-28 |
Neumirna Therapeutics Aps |
Antisense oligonucleotides targeting adenosine kinase
|
EP4396352A2
(de)
|
2021-09-01 |
2024-07-10 |
Ionis Pharmaceuticals, Inc. |
Verbindungen und verfahren zur reduzierung der dmpk-expression
|
MX2024002640A
(es)
|
2021-09-01 |
2024-07-19 |
Entrada Therapeutics Inc |
Compuestos y metodos para salto de exon 44 en la distrofia muscular de duchenne.
|
EP4144841A1
(de)
|
2021-09-07 |
2023-03-08 |
Bayer AG |
Neue programmierbare rna-endonuklease-systeme mit verbesserter pam-spezifität und deren verwendung
|
EP4401742A2
(de)
|
2021-09-17 |
2024-07-24 |
Alnylam Pharmaceuticals, Inc. |
Irna-zusammensetzungen und verfahren zur dämpfung der komplementkomponente 3 (c3)
|
WO2023043280A1
(ko)
|
2021-09-17 |
2023-03-23 |
주식회사 씨젠 |
합성 비자연 염기를 포함하는 태그 올리고뉴클레오타이드를 이용한 타겟 핵산 서열의 검출
|
CA3232420A1
(en)
|
2021-09-20 |
2023-03-23 |
Alnylam Pharmaceuticals, Inc. |
Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
|
JP2024536132A
(ja)
|
2021-09-29 |
2024-10-04 |
エフ. ホフマン-ラ ロシュ アーゲー |
Rna編集方法
|
CA3233755A1
(en)
|
2021-10-01 |
2023-04-06 |
Adarx Pharmaceuticals, Inc. |
Prekallikrein-modulating compositions and methods of use thereof
|
WO2023064530A1
(en)
|
2021-10-15 |
2023-04-20 |
Alnylam Pharmaceuticals, Inc. |
Extra-hepatic delivery irna compositions and methods of use thereof
|
CA3234835A1
(en)
|
2021-10-22 |
2023-04-27 |
Korro Bio, Inc. |
Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
|
IL312399A
(en)
|
2021-10-29 |
2024-06-01 |
Alnylam Pharmaceuticals Inc |
Complement factor B (CFB) iRNA compositions and methods of using them
|
TW202334418A
(zh)
|
2021-10-29 |
2023-09-01 |
美商艾拉倫製藥股份有限公司 |
杭丁頓(HTT)iRNA劑組成物及其使用方法
|
EP4428238A1
(de)
|
2021-11-02 |
2024-09-11 |
Rena Therapeutics Inc. |
Ligandgebundener nukleinsäurekomplex
|
CN118318042A
(zh)
|
2021-11-03 |
2024-07-09 |
豪夫迈·罗氏有限公司 |
用于调节载脂蛋白e4表达的寡核苷酸
|
EP4430184A2
(de)
|
2021-11-11 |
2024-09-18 |
F. Hoffmann-La Roche AG |
Pharmazeutische kombinationen zur behandlung von hbv
|
EP4433098A1
(de)
|
2021-11-18 |
2024-09-25 |
Cornell University |
Microrna-abhängige mrna-schalter für gewebespezifische mrna-basierte therapien
|
WO2023092102A1
(en)
|
2021-11-19 |
2023-05-25 |
Sanegene Bio Usa Inc. |
Double stranded rna targeting angiopoietin-like 3 (angptl-3) and methods of use thereof
|
EP4444882A1
(de)
|
2021-12-07 |
2024-10-16 |
F. Hoffmann-La Roche AG |
Antisense-oligonukleotide zum targeting von actl6b
|
GB202117758D0
(en)
|
2021-12-09 |
2022-01-26 |
Ucl Business Ltd |
Therapeutics for the treatment of neurodegenerative disorders
|
EP4448106A1
(de)
|
2021-12-17 |
2024-10-23 |
Hoffmann-La Roche Inc. |
Kombination von oligonukleotiden zur modulierung von stel1 und fubp1
|
WO2023111336A1
(en)
|
2021-12-17 |
2023-06-22 |
F. Hoffmann-La Roche Ag |
Oligonucleotide gba agonists
|
WO2023117738A1
(en)
|
2021-12-20 |
2023-06-29 |
F. Hoffmann-La Roche Ag |
Threose nucleic acid antisense oligonucleotides and methods thereof
|
CA3242118A1
(en)
|
2021-12-22 |
2023-06-29 |
Alfica Sehgal |
Modulation of gene transcription using antisense oligonucleotides targeting regulatory rnas
|
WO2023118068A1
(en)
|
2021-12-23 |
2023-06-29 |
Bayer Aktiengesellschaft |
Novel small type v rna programmable endonuclease systems
|
CN118613268A
(zh)
|
2022-01-20 |
2024-09-06 |
基因泰克公司 |
用于调节tmem106b表达的反义寡核苷酸
|
WO2023141314A2
(en)
|
2022-01-24 |
2023-07-27 |
Alnylam Pharmaceuticals, Inc. |
Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
|
WO2023152369A1
(en)
|
2022-02-14 |
2023-08-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Nucleic acid mir-9 inhibitor for the treatment of cystic fibrosis
|
AR128558A1
(es)
|
2022-02-21 |
2024-05-22 |
Hoffmann La Roche |
Oligonucleótido antisentido
|
WO2023212625A1
(en)
|
2022-04-28 |
2023-11-02 |
AcuraStem Incorporated |
Syf2 antisense oligonucleotides
|
WO2023220561A1
(en)
|
2022-05-09 |
2023-11-16 |
Sanegene Bio Usa Inc. |
Double stranded rna targeting 17-beta hydroxysteroiddehydrogenase 13 (hsd17b13) and methods of use thereof
|
WO2023217890A1
(en)
|
2022-05-10 |
2023-11-16 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting cfp-elk1 intergene region
|
WO2023220744A2
(en)
|
2022-05-13 |
2023-11-16 |
Alnylam Pharmaceuticals, Inc. |
Single-stranded loop oligonucleotides
|
TW202409276A
(zh)
|
2022-05-18 |
2024-03-01 |
瑞士商赫孚孟拉羅股份公司 |
改良之靶向rna結合蛋白位點的寡核苷酸
|
WO2023240277A2
(en)
|
2022-06-10 |
2023-12-14 |
Camp4 Therapeutics Corporation |
Methods of modulating progranulin expression using antisense oligonucleotides targeting regulatory rnas
|
WO2023237587A1
(en)
|
2022-06-10 |
2023-12-14 |
Bayer Aktiengesellschaft |
Novel small type v rna programmable endonuclease systems
|
WO2023242324A1
(en)
|
2022-06-17 |
2023-12-21 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides for targeting progranulin
|
WO2024006999A2
(en)
|
2022-06-30 |
2024-01-04 |
Alnylam Pharmaceuticals, Inc. |
Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
|
WO2024017990A1
(en)
|
2022-07-21 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating chronic pain disorders
|
US20240052348A1
(en)
|
2022-08-05 |
2024-02-15 |
Sanegene Bio Usa Inc. |
Double stranded rna targeting angiotensinogen (agt) and methods of use thereof
|
WO2024039776A2
(en)
|
2022-08-18 |
2024-02-22 |
Alnylam Pharmaceuticals, Inc. |
Universal non-targeting sirna compositions and methods of use thereof
|
EP4332221A1
(de)
|
2022-08-29 |
2024-03-06 |
Roche Innovation Center Copenhagen A/S |
Threose-nukleinsäure-antisense-oligonukleotide und verfahren dafür
|
EP4332239A1
(de)
|
2022-08-30 |
2024-03-06 |
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l. |
Mir-basierter test zur diagnose und prognose von gastro-entero-pankreatischen neuroendokrinen tumoren
|
WO2024052403A1
(en)
|
2022-09-06 |
2024-03-14 |
F. Hoffmann-La Roche Ag |
Double-stranded rna molecule for administration to the eye
|
WO2024059165A1
(en)
|
2022-09-15 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
|
WO2024073042A1
(en)
|
2022-09-30 |
2024-04-04 |
Entrada Therapeutics, Inc. |
Ocular delivery of therapeutic agents
|
WO2024073732A1
(en)
|
2022-09-30 |
2024-04-04 |
Alnylam Pharmaceuticals, Inc. |
Modified double-stranded rna agents
|
US20240175026A1
(en)
|
2022-10-14 |
2024-05-30 |
Sanegene Bio Usa Inc. |
Small interfering rna targeting c3 and uses thereof
|
WO2024098061A2
(en)
|
2022-11-04 |
2024-05-10 |
Genkardia Inc. |
Oligonucleotide-based therapeutics targeting cyclin d2 for the treatment of heart failure
|
WO2024104914A1
(en)
|
2022-11-14 |
2024-05-23 |
BioNTech SE |
Rna capping efficiency assay
|
WO2024119145A1
(en)
|
2022-12-01 |
2024-06-06 |
Camp4 Therapeutics Corporation |
Modulation of syngap1 gene transcription using antisense oligonucleotides targeting regulatory rnas
|
WO2024126654A1
(en)
|
2022-12-14 |
2024-06-20 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting actl6b
|
WO2024137590A2
(en)
|
2022-12-19 |
2024-06-27 |
Sanegene Bio Usa Inc. |
Small interfering rna targeting cfb and uses thereof
|
WO2024146935A1
(en)
|
2023-01-06 |
2024-07-11 |
Institut National de la Santé et de la Recherche Médicale |
Intravenous administration of antisense oligonucleotides for the treatment of pain
|
WO2024155986A2
(en)
|
2023-01-20 |
2024-07-25 |
AcuraStem Incorporated |
Unc13a antisense oligonucleotides
|
WO2024160756A1
(en)
|
2023-01-30 |
2024-08-08 |
Vib Vzw |
Suppressors of tauopathies
|
WO2024163651A2
(en)
|
2023-01-31 |
2024-08-08 |
AcuraStem Incorporated |
Syf2 antisense oligonucleotides
|
WO2024167945A1
(en)
|
2023-02-06 |
2024-08-15 |
AcuraStem Incorporated |
Pikfyve antisense oligonucleotides
|
WO2024168010A2
(en)
|
2023-02-09 |
2024-08-15 |
Alnylam Pharmaceuticals, Inc. |
Reversir molecules and methods of use thereof
|
WO2024175586A2
(en)
|
2023-02-21 |
2024-08-29 |
Vib Vzw |
Inhibitors of synaptogyrin-3 expression
|
WO2024175588A1
(en)
|
2023-02-21 |
2024-08-29 |
Vib Vzw |
Oligonucleotides for modulating synaptogyrin-3 expression
|
WO2024175707A1
(en)
|
2023-02-22 |
2024-08-29 |
Helmholtz-Zentrum für Infektionsforschung GmbH |
A synthetic oligonucleotide for treating nidovirales infections
|
WO2024175111A2
(en)
|
2023-02-24 |
2024-08-29 |
Suzhou Sanegene Bio Inc. |
Small interfering rna targeting hbv and uses thereof
|
US20240309380A1
(en)
|
2023-03-03 |
2024-09-19 |
Sanegene Bio Usa Inc. |
Small interfering rna targeting apoc3 and uses thereof
|
EP4450626A1
(de)
|
2023-04-21 |
2024-10-23 |
IFOM - Istituto Fondazione di Oncologia Molecolare ETS |
Frnip2-inhibitoren zur behandlung von ataxie telangiectasia
|